Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)

Wardrop D, Estcourt LJ, Brunskill SJ, Doree C, Trivella M, Stanworth S, Murphy MF

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2013, Issue 7

http://www.thecochranelibrary.com

WILEY
# Table of Contents

- **Header** ............................................... 1
- **Abstract** ........................................... 1
- **Plain Language Summary** ................................. 2
- **Summary of Findings for the Main Comparison** .......... 4
- **Background** ........................................... 6
- **Objectives** ............................................. 7
- **Methods** ............................................... 7
- **Results** ............................................... 10
  - Figure 1. .............................................. 11
  - Figure 2. .............................................. 14
- **Discussion** ............................................ 18
- **Authors’ Conclusions** ................................ 20
- **Acknowledgements** ..................................... 20
- **References** ............................................ 21
- **Characteristics of Studies** ............................... 24
- **Data and Analyses** .................................... 36
- **Additional Tables** .................................... 36
- **Appendices** ........................................... 41
- **Contributions of Authors** ................................ 48
- **Declarations of Interest** ................................ 48
- **Sources of Support** .................................... 48

---

*Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)*

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abstract

Background

Patients with haematological disorders are frequently at risk of severe or life-threatening bleeding as a result of thrombocytopenia. This is despite the routine use of prophylactic platelet transfusions (PlTx) to prevent bleeding once the platelet count falls below a certain threshold. PlTx are not without risk and adverse events may be life-threatening. A possible adjunct to prophylactic PlTxs is the use of antifibrinolytics, specifically the lysine analogues tranexamic acid (TXA) and epsilon aminocaproic acid (EACA).

Objectives

To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders.

Search methods

We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL Issue 12, 2012), MEDLINE (1948 to 10 January 2013), EMBASE (1980 to 10 January 2013), CINAHL (1982 to 10 January 2013), PubMed (e-publications only) and the Transfusion Evidence Library (1980 to January 2013). We also searched several international and ongoing trial databases to 10 January 2013 and citation-tracked relevant reference lists.

Selection criteria

RCTs involving patients with haematological disorders, who would routinely require prophylactic platelet transfusions to prevent bleeding. We only included trials involving the use of the lysine analogues TXA and EACA.

Data collection and analysis

Two authors independently screened all electronically derived citations and abstracts of papers, identified by the review search strategy, for relevance. Two authors independently assessed the full text of all potentially relevant trials for eligibility, completed the data extraction and assessed the studies for risk of bias using The Cochrane Collaboration’s ‘Risk of bias’ tool. We requested missing data from one author but the data were no longer available. The outcomes are reported narratively: we performed no meta-analyses because of the heterogeneity of the available data.
Main results

Of 470 articles initially identified, 436 were excluded on the basis of the title and abstract. We reviewed 34 full-text articles from which four studies reported in five articles were eligible for inclusion. We did not identify any RCTs which compared TXA with EACA. We did not identify any ongoing RCTs.

One cross-over TXA study (eight patients) was excluded from the outcome analysis because data from this study were at a high risk of bias. Data from the other three studies were all at unclear risk of bias due to lack of reporting of study methodology.

Three studies (two TXA (12 to 56 patients), one EACA (18 patients)) reported in four articles (published 1983 to 1995) were included in the narrative review. All three studies compared the drug with placebo.

All studies reported bleeding, but it was reported in different ways. All three studies suggested antifibrinolytics reduced the risk of bleeding. The first study showed a difference in average bleeding score of 42 in placebo (P) versus three (TXA). The second study only showed a difference in bleeding episodes during consolidation chemotherapy, with a mean of 2.6 episodes/patient (standard deviation (SD) 2.2) (P) versus a mean of 1.1 episodes/patient (SD 1.4) (TXA). The third study reported bleeding on 50% of days at risk (P) versus bleeding on 31% of days at risk (EACA).

Two studies (68 patients) reported thromboembolism and no events occurred.

All three studies reported a reduction in PlTx usage. The first study reported a difference of 222 platelet units (P) versus 69 platelet units (TXA). The second study only showed a difference in total platelet usage during consolidation chemotherapy, with a mean of 9.3 units (SD 3.3) (P) versus 3.7 (SD 4.1) (TXA). The third study reported one PlTx every 10.5 days at risk (P) versus one PlTx every 13.3 days at risk (EACA).

Two studies reported red cell transfusion requirements and one study found a reduction in red cell transfusion usage.

One study reported death due to bleeding as an outcome measure and none occurred.

Only one study reported adverse events of TXA as an outcome measure and none occurred.

None of the studies reported on the following pre-specified outcomes: overall mortality, adverse events of transfusion, disseminated intravascular coagulation (DIC) or quality of life (QoL).

Authors’ conclusions

Our results indicate that the evidence available for the use of antifibrinolytics in haematology patients is very limited. The only available data suggest that TXA and EACA may be useful adjuncts to platelet transfusions so that platelet use, and the complications associated with their use, can be reduced. However, the trials were too small to assess whether antifibrinolytics increased the risk of thromboembolic events. Large, high-quality RCTs are required before antifibrinolytics can be demonstrated to be efficacious and safe in widespread clinical practice.

Plain Language Summary

Antifibrinolytics (tranexamic acid and epsilon-aminocaproic acid) to prevent bleeding in patients with low platelets due to bone marrow failure

Patients with haematological (blood) cancers and other blood disorders are frequently at risk of severe or life-threatening bleeding from having low platelets (thrombocytopenia). This may be from bone marrow failure due to an underlying blood disorder but also from the toxic effect of treatment (chemotherapy) on the bone marrow. Such patients can be given prophylactic platelet transfusions (from donations) to prevent bleeding if their own platelet counts are too low. These transfusions are not without risks, ranging from mild reactions like fevers to more serious, or even life-threatening, consequences such as infections transmitted to the patient from the transfused platelets, despite stringent attempts to prevent this.

Clearly, ways to safely prevent bleeding in thrombocytopenic patients whilst also minimising exposure to transfused platelets would be welcomed. One possible way of achieving these goals is the use of antifibrinolytics, known as lysine analogues: tranexamic acid (TXA) and epsilon aminocaproic acid (EACA). These medications help to stabilise the clots that form after bleeding, therefore reducing the chances of further bleeding as well as the need for transfusing platelets. There may be risks associated with the use of TXA and EACA;
the most important being an increased risk of forming unwanted blood clots (such as deep vein thrombosis (DVT)), which could be potentially life-threatening.

This review has been designed to establish the efficacy and safety of these drugs, specifically in patients with blood disorders, who are at risk of thrombocytopenia and bleeding, either due to the disorder itself, its treatment or both. After searching the available literature up to January 2013, only four trials containing ninety-five patients were eligible for inclusion in our review. Three studies suggested that antifibrinolytics may reduce bleeding and also the need for platelet transfusions. Two studies reported that no blood clots occurred but it was unclear whether these agents reduced the need for other types of transfusions (i.e. red blood cell transfusions to treat and prevent anaemia). The numbers of patients involved were small, and the quality of the evidence was very low, making it difficult to draw conclusions or make recommendations regarding the usefulness and safety of antifibrinolytics. Further, larger trials are needed to determine whether antifibrinolytics can be recommended for widespread use in patients with blood disorders.
Antifibrinolytics (lysine analogues) compared to placebo to prevent bleeding in patients with haematological disorders

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td>Gallardo 1983 saw a reduction in minor bleeding; Avvisati 1989 and Shpilberg 1995 saw a reduction in the number of bleeding events</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>Antifibrinolytics (lysine analogues)</td>
<td></td>
<td></td>
<td>No patients within the Avvisati 1989 or Shpilberg 1995 studies had an episode of thromboembolism. Gallardo 1983 only reported no deaths due to thrombosis.</td>
</tr>
</tbody>
</table>

**Number of patients with any bleeding**

See comment

Not estimable

86 (3 studies)

⊕⊕⊕ very low

Gallardo 1983 saw a reduction in minor bleeding; Avvisati 1989 and Shpilberg 1995 saw a reduction in the number of bleeding events.

**Number of patients with thromboembolism**

See comment

Not estimable

68 (2 studies)

⊕⊕⊕ very low

No patients within the Avvisati 1989 or Shpilberg 1995 studies had an episode of thromboembolism. Gallardo 1983 only reported no deaths due to thrombosis.

**Mortality (all-cause)**

See comment

Not estimable

0 (0)

See comment

None of the studies reported all-cause mortality. Shpilberg 1995 reported no deaths due
Antifibrinolitics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)

<table>
<thead>
<tr>
<th>Number of platelet transfusions per patient</th>
<th>See comment</th>
<th>See comment</th>
<th>Not estimable</th>
<th>0 (0)</th>
<th>See comment</th>
<th>None of the studies reported the number of platelet transfusions per patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events of transfusions</td>
<td>See comment</td>
<td>See comment</td>
<td>Not estimable</td>
<td>0 (0)</td>
<td>See comment</td>
<td>None of the studies reported adverse events due to blood transfusions</td>
</tr>
<tr>
<td>Adverse events of antifibrinolytic agents</td>
<td>See comment</td>
<td>See comment</td>
<td>Not estimable</td>
<td>74 (2 studies)</td>
<td>⚫⚫⚫⚫ very low&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>Shpilberg 1995 reported no side effects were observed and Gallardo 1983 stated side effects were minimal but no further information was provided</td>
</tr>
</tbody>
</table>

*No meta-analyses were performed within this review and therefore no comparative risks could be calculated.

<sup>1</sup> One study (Fricke 1991) was included within the review but no data were extracted from this study. This was because Fricke 1991 had significant flaws within the study design (see Risk of bias in included studies and Characteristics of included studies) and no viable data could be extracted from the study report.

CI: confidence interval

**GRADE Working Group grades of evidence**

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup> A full assessment of the quality of the evidence was limited by a lack of reporting. However, selective outcome reporting was present in Gallardo 1983.

<sup>2</sup> Within all three studies there were only 86 participants. This is significantly below the optimal information size (OIS) (Pogue 1997).
**BACKGROUND**

**Description of the condition**

Patients with haematological disorders are frequently at risk of severe or life-threatening bleeding as a result of thrombocytopenia. This is commonly a result of the underlying pathology, a side effect of treatment with chemotherapeutic agents, or both. Patients are administered therapeutic platelet transfusions to treat bleeding and prophylactic platelet transfusions to prevent bleeding once the platelet count falls below a certain threshold (10 x $10^9$/l, or higher if the risk of haemorrhage is raised, e.g. sepsis or the presence of another bleeding diathesis) (BCSH 2003). A large, recent randomised controlled trial (RCT) of platelet transfusions involving 1272 patients with haematological or solid tumours showed that the baseline level of clinically significant bleeding does not appear to depend on the platelet count once it is above 5 x $10^9$/l. The risk of bleeding was 17% per day at platelet counts above 5 x $10^9$/l, compared with 25% per day at counts below this level (Slichter 2010). This confirms earlier work from a large, retrospective observational study of 2942 thrombocytopenic adult patients that showed that the platelet count did not affect the risk of severe or life-threatening bleeding (World Health Organization (WHO) scale 3 or 4) (Friedmann 2002).

Platelet transfusions are not without risks. Adverse events may range from mild reactions, such as fever (one in five transfusions) (Heddle 2009) to more serious and even life-threatening events such as bacterial sepsis from transfusion transmitted infection (one in 10,000 transfusions) (Heddle 2009) or transfusion-related acute lung injury (TRALI) (Pavlovsky 1985). Patients may also become refractory to platelet transfusions; the incidence increases with the number of platelet transfusions administered (Slichter 2005). Once refractory, the ability to treat bleeding with platelet transfusions becomes more difficult, requiring expensive, specially matched platelets that can be difficult to source. Furthermore, the financial cost of platelet transfusions is considerable. Around 302,000 adult doses of platelets are issued in the UK each year (Bolton-Maggs 2012) at an annual cost of approximately GBP 68.5 million (Llewellyn 2009) and up to two-thirds (67%) of these are given to patients with haematological malignancies (Cameron 2007; Greenwood 2007; Pendry 2011).

Clearly interventions that can safely prevent bleeding in thrombocytopenic patients, whilst minimising patient exposure to allogeneic platelets and reducing financial costs, would be welcomed. One possible adjunct, or even an alternative, to prophylactic platelet transfusions is the use of antifibrinolytics, specifically lysine analogues, such as tranexamic acid (TXA) and epsilon aminocaproic acid (EACA).

This systematic review has been designed to establish the safety and efficacy of these agents specifically in patients with haematological disorders who are at risk of thrombocytopenia and bleeding, either due to the disorder itself, its treatment or both.

**Description of the intervention**

There have been several Cochrane reviews examining the efficacy of antifibrinolytics in preventing bleeding in other patient groups (Gurusamy 2011; Henry 2011; Martin-Hirsch 2010; Novikova 2011; Roos 2008; Tzortzopoulou 2008). The largest of these involved over 25,000 patients, and assessed the use of TXA, EACA, and another type of antifibrinolytic, aprotinin, with respect to the minimisation of perioperative allogeneic blood transfusions (Henry 2011). However, no systematic review has addressed the use of antifibrinolytics to prevent bleeding in haematology patients.

TXA and EACA are effective in surgical patients (Henry 2011; Ker 2012). They have been used widely in both elective and emergency surgery and have been shown to reduce both blood loss and the need for blood transfusions. In the largest Cochrane review, 65 trials compared TXA with control and comprised a total of 4842 patients of whom 2528 were randomised to TXA. TXA versus control showed a relative reduction in the need for allogeneic blood transfusion of 39% (Henry 2011). A significant effect was also observed for EACA; in 16 trials comparing EACA with control (with a total of 1035 patients, of whom 530 were randomised to EACA), there was a relative reduction in the need for allogeneic blood transfusion of 19% (Henry 2011). In the literature there appears to be a paucity of direct comparisons between TXA and EACA but they appear comparable in terms of safety and efficacy. A recent study comparing TXA and EACA in 234 paediatric patients undergoing cardiac surgery found no significant differences between the two in terms of transfusion requirement, rates of revision for re-bleeding, postoperative complications (such as seizures, renal failure and thrombosis) and in-house mortality (Martin 2011).

TXA is effective in trauma patients. In a recent large RCT (CRASH-2), TXA has been shown to significantly reduce the risk of death due to bleeding in trauma patients with significant haemorrhage (Shakur 2010). TXA has also been found to be highly cost-effective; it is relatively inexpensive and its use in preventing bleeding may obviate the need for additional transfusion of blood products and longer stays in hospital. In a recent cost-effectiveness analysis of the CRASH-2 trial, Guerriero 2011 reported that the administration of TXA within three hours of injury to bleeding trauma patients has been estimated to save 755 life years (LYs) per 1000 trauma patients in the UK, and the incremental cost of giving TXA versus not giving TXA was estimated at USD 48,002 in the UK, equivalent of a cost of around USD 64 per life-year saved.

TXA and EACA are commonly used to treat bleeding in patients with haematological disorders (Lozano 2013). They are also used to prevent bleeding in patients who are refractory to platelet transfusions (Lozano 2013). It therefore seems possible that lysine analogues may also be cost-effective in preventing bleeding in patients with haematological disorders with severe thrombocytopenia who are not refractory to platelet transfusions.

Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
TXA and EACA are the only antifibrinolytics in common use. Aprotinin, a naturally occurring serine protease inhibitor, was once commonly used as a blood-sparing agent, particularly in cardiac surgery. However, it is now used rarely due to concerns of an increased risk of cardiovascular complications and death (Henry 2011). This was because the BART (Blood Conservation Using Antifibrinolytics in a Randomized Trial) multi-centre blinded RCT was terminated early when a higher rate of death was seen in patients receiving aprotinin (Fergusson 2008). This study was designed to determine whether aprotinin was superior to either TXA or EACA in decreasing massive postoperative bleeding in patients undergoing high-risk cardiac surgery. A modest and non-significant reduction in the risk of massive bleeding was observed in the aprotinin arm compared to TXA or EACA but the rate of death from any cause at 30 days was 6.0% in the aprotinin group, compared with 3.9% (relative risk 1.55; 95% CI 0.99 to 2.42) and 4.0% (relative risk 1.52; 95% CI 0.98 to 2.36) in the TXA and EACA groups, respectively. The authors concluded the negative mortality trend associated with aprotinin, as compared with the lysine analogues, precluded its use in high-risk cardiac surgery (Fergusson 2008).

Although TXA and EACA have been shown to be effective in other patient groups there is a concern that these drugs may increase the rate of thromboembolism (Henry 2011). This is particularly important in haematology patients, as patients with an underlying malignancy already have a higher rate of thromboembolic disease than the general population. In a retrospective cohort study of thromboembolism in hospitalised neutropenic cancer patients, 4% (593/14,600) of acute leukaemia patients developed venous thromboembolism and 1.9% (279/14,600) of acute leukaemia patients developed arterial thromboembolism (Khorana 2006). Furthermore, TXA and EACA may increase the risk of disseminated intravascular coagulation (DIC). In a subsequent exploratory analysis of the CRASH-2 trial, late treatment with TXA (> 3 hours) seemed to increase the risk of death in trauma patients due to bleeding (Roberts 2011). The mechanism underlying this could not be readily explained, but the authors noted that one possibility related to the evolution of DIC, a condition in which lysine analogues could be contraindicated (Prentice 1980; Roberts 2011; Sawamura 2009). This highlights a serious need for caution in the use of these agents in patients with haematological malignancies as they are at increased risk of DIC (Franchini 2010). Overt cases of DIC are diagnosed in approximately 15% of patients with acute leukaemia and bleeding manifestations tend to prevail over thrombosis (Franchini 2010).

Despite these important concerns, it should be noted that in the recent large Cochrane review of over 25,000 patients (Henry 2011), the use of TXA or EACA was not associated with an increased risk of mortality, myocardial infarction, deep vein thrombosis, stroke, incidence of renal dysfunction or length of hospital stay, although the data were sparse. In addition, there have been small RCTs assessing the efficacy of TXA versus placebo in haematology patients that did not report an increase in thromboembolic complications, although sample sizes were small (Avvisati 1989; Shpilberg 1995).

**How the intervention might work**

Tranexamic acid and epsilon aminocaproic acid are synthetic analogues of the amino acid lysine and act by blocking the lysine binding sites on plasminogen. This inhibits the formation of plasmin and therefore prevents fibrinolysis, leading to improved haemostasis (Okamoto 1997). In vitro tranexamic acid is approximately 10 times more potent than aminocaproic acid and binds much more strongly to the sites on the plasminogen molecule (Faught 1998).

It is plausible that if these lysine analogues are effective and safe, the bleeding risk in patients with haematological disorders could be reduced, and the requirement for prophylactic platelet transfusions could be minimised.

**Why it is important to do this review**

Clearly, it is essential to reduce the risk of bleeding in patients with haematological disorders and thrombocytopenia as effectively and as safely as possible. Since the CRASH-2 trial (Roberts 2011) and two large systematic reviews (Henry 2011; Ker 2012) have shown antifibrinolytics to be effective in other patient groups there has been renewed interest in using this drug to prevent bleeding in patients with haematological disorders.

The key questions to address are:

1. What is the efficacy of lysine analogues in preventing bleeding in thrombocytopenic patients with haematological disorders?
2. Can the number of prophylactic platelet transfusions be minimised?
3. Does the use of lysine analogues lead to a significant increase in the incidence of thromboembolism?

If lysine analogues are shown to be effective whilst demonstrating an acceptable safety profile, there would be a strong case for their routine use in patients with haematological disorders at significant risk of severe thrombocytopenia. A systematic review is therefore required before any proposed introduction of these agents in patients with haematological disorders.

**OBJECTIVES**

To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders.

**METHODS**
Criteria for considering studies for this review

Types of studies
We only included RCTs in this review, irrespective of language or publication status.

Types of participants
All patients, of any age, with a haematological disorder (malignant or non-malignant) who were severely thrombocytopenic due to bone marrow failure (secondary to the disease or to its treatment) and required platelet transfusions. We excluded patients with immune thrombocytopenic purpura (ITP) because these patients are not usually treated with platelet transfusions.

Types of interventions
We only reviewed antifibrinolytic agents that act by competitively inhibiting the conversion of plasminogen to plasmin (lysine analogues), i.e. tranexamic acid and epsilonaminocaproic acid. Aprotinin is a serine protease and has a different mechanism of action. We included the following comparisons:
- TXA versus placebo;
- EACA versus placebo;
- TXA versus EACA.

We included any dose of the medication, administered either orally or intravenously.

Types of outcome measures

Primary outcomes
- Number, site and severity of bleeding (i.e. any bleeding, clinically significant bleeding, life-threatening bleeding)
- Thromboembolism (venous and arterial)

Secondary outcomes
- Mortality (all causes)
- Mortality (secondary to bleeding)
- Mortality (secondary to thromboembolism)
- Laboratory assessment of fibrinolysis
- Number of platelet transfusions
- Number of red cell transfusions
- Adverse events of antifibrinolytic agents
- Adverse events of transfusions (e.g. transfusion reactions, antibody development)
- Disseminated intravascular coagulation (DIC)
- Quality of life (QoL)

We listed both primary outcomes in 'Summary of findings' tables, as well as the number of red cell and platelet transfusions.

Search methods for identification of studies

We formulated search strategies in collaboration with the Cochrane Haematological Malignancies Group.

Electronic searches
Our Information Specialist (CD) formulated the search strategies used in collaboration with the Cochrane Haematological Malignancies Group. Relevant RCTs were searched for in the following electronic databases:
- Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 12, 2012) (Appendix 1);
- MEDLINE (from 1948 to 10 January 2013) (Appendix 2);
- EMBASE (from 1980 to 10 January 2013) (Appendix 3);
- CINAHL (from 1982 to 10 January 2013) (Appendix 4);
- PubMed (e-publications as of 10 January 2013 only) (Appendix 5);
- LILACS (from 1982 to 10 January 2013) (Appendix 6);
- KoreaMed (from 1982 to 10 January 2013) (Appendix 6);
- PakMediNet (from 2001 to 10 January 2013) (Appendix 6);
- IndMed (from 1985 to 10 January 2013) (Appendix 6);
- UKBTSSRITransfusion Evidence Library (www.transfusionevidencelibrary.com) (from 1980 to 10 January 2013) (Appendix 7);
- Web of Science, Conference Proceedings Citation Index (from 1990 to 10 January 2013) (Appendix 8).

Ongoing trial databases (all years) were also searched on 10 January 2013:
- ClinicalTrials.gov (Appendix 9);
- WHO International Clinical Trials Registry Platform (ICTRP) (Appendix 9);
- ISRCTN Register (Appendix 10);
- EU Clinical Trials Register (EUDRACT) (Appendix 10);
- UMIN-CTR Japanese Clinical Trials Registry and the Hong Kong Clinical Trials Registry (Appendix 10).

Searches in MEDLINE, EMBASE and CINAHL were combined with adaptations of the RCT search filters as detailed in the Cochrane Handbook for Systematic Reviews of Interventions (Lefebvre 2011). Searches were not restricted by either date or language.

Searching other resources
We augmented database searching with the following.
- Handsearching of reference lists
  - We checked references of all identified trials, relevant review articles and current treatment guidelines for further literature.
  - We limited these searches to the 'first generation' reference lists.
- Personal contacts
We contacted authors of relevant studies, study groups and experts worldwide who are known to be active in the field for unpublished material or further information on ongoing studies.

Data collection and analysis

Selection of studies
One author (CD) initially screened all search results for relevance against the eligibility criteria and disregarded all those that were clearly irrelevant. Thereafter, two review authors (DW, LE) independently screened all the remaining hits for relevance against the full eligibility criteria. We retrieved full-text papers for all those references where we were unable to decide on eligibility based on title and abstract alone. We sought further information from the study authors where articles contained insufficient data to make a decision about eligibility. We resolved differences of opinion through discussion and consensus. We tabulated studies which did not meet our eligibility criteria (Characteristics of excluded studies).

Data extraction and management
Two review authors (DW, SB) conducted data extraction according to the guidelines proposed by The Cochrane Collaboration (Higgins 2011a). We resolved potential disagreements between the authors by consensus. If an agreement could not be reached, a third author (LE) was asked to give her opinion. We were not blinded to the names of authors, institutions, journals or the outcomes of the trials. We used a standardised data extraction form to record the following items:

1. General information: review author’s name, date of data extraction, study ID, first author of study, author’s contact address (if available), citation of paper, objectives of the trial.
2. Trial details: trial design, location, setting, sample size, power calculation, inclusion and exclusion criteria, reasons for exclusion, comparability of groups, length of follow-up, stratification, stopping rules described, results, conclusion and funding.
3. ‘Risk of bias’ assessment: sequence generation, allocation concealment, blinding (participants, personnel, outcome assessors), incomplete outcome data, selective outcome reporting and other sources of bias.
4. Characteristics of participants: age, gender, ethnicity, total number recruited, total number randomised, total number analysed, types of haematological disease, lost to follow-up numbers, drop outs (percentage in each arm) with reasons, protocol violations, current treatment, previous treatments.
5. Interventions: experimental and control interventions, type of antifibrinolytic given, timing of intervention, compliance to interventions, additional interventions given especially in relation to platelet and red cell transfusions, any differences between interventions.

6. Outcomes measured: number, site and severity of bleeding episodes; thromboembolism (venous and arterial); mortality (all causes); mortality due to haemorrhage; mortality due to thromboembolism; laboratory assessment of fibrinolysis; number of platelet transfusions; number of red cell transfusions; adverse effects of antifibrinolytic agents; adverse effects of transfusions (e.g. transfusion reactions, development of platelet antibodies); DIC.

We retrieved the data from both full-text and abstract reports of studies. Where these sources did not provide sufficient information, we contacted authors, study groups or companies for additional details.

Assessment of risk of bias in included studies
Three authors (DW, SB, LE) assessed all included studies for possible risk of bias as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011c). The assessment included information about the design, conduct and analysis of the trial. We evaluated whether the studies are at a low risk, high risk or uncertain risk of bias. To assess risk of bias, the following questions were included in the ‘Risk of bias’ table for each included study:

- Was the allocation sequence adequately generated?
- Was allocation adequately concealed?
- Was the knowledge of the allocated intervention adequately prevented during the study?
- Were incomplete outcome data adequately addressed?
- Are reports of the study free of selective outcome reporting?
- Was the study apparently free of other problems that could put it at risk of bias?

Measures of treatment effect
We performed this according to the recommendations in the Cochrane Handbook for Systematic Reviews of Interventions (Deeks 2011). For dichotomous outcomes we recorded the numbers of outcomes in treatment and control groups. For continuous outcomes, we recorded the mean and standard deviations.

Dealing with missing data
We performed this according to the recommendations in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b). We contacted one author by email in order to obtain information that was missing or unclear in the published report. One author responded to our email request but was unable to provide any further information (Gallardo 1983). We recorded the number of patients lost to follow-up for each trial.
Assessment of heterogeneity
We did not perform a formal assessment of heterogeneity because it was not possible to perform meta-analyses due to the nature of the data reported by the included studies. (Deeks 2011).

Assessment of reporting biases
We did not perform a formal assessment of reporting biases because there were not enough data to support such an assessment and no meta-analyses of outcome data were performed (Sterne 2011).

Data synthesis
We performed a narrative synthesis of the findings from the included studies, structured around the type of antifibrinolytic. No statistical analyses were performed because the studies reported outcomes in different ways and these results could not be integrated.
We used the GRADE profiler to create 'Summary of findings' tables as suggested in the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2011).

Subgroup analysis and investigation of heterogeneity
We pre-specified three subgroup analyses:
• Age (children/adults);
• Underlying haematological diagnoses;
• Type of treatment (e.g. chemotherapy, autologous and allogeneic transplantation, immunosuppression).

However, we did not perform any subgroup analyses due to a lack of outcome data.

Sensitivity analysis
We did not perform a formal sensitivity analysis because we performed no meta-analyses.

RESULTS

Description of studies
See Characteristics of included studies; Characteristics of excluded studies and Table 1.

Results of the search
See PRISMA diagram Figure 1. The original search identified 953 records through database searching with an additional 12 records identified through other sources (principally the handsearching of reference lists of included studies). After duplicates were removed, we screened 470 records in abstract form for eligibility and excluded 436 records. Of the remaining records, we retrieved and assessed 34 full-text articles for eligibility and excluded 29 due to either: not being an RCT (N = 12), wrong patient group (N = 8), because the article was a review (N = 6) or ineligible intervention (N = 3).
Figure 1. Study flow diagram.

963 records identified through database searching

12 additional records identified through other sources

470 records after duplicates removed

470 records screened

496 records excluded on the basis of the abstract

29 full-text articles excluded
Wrong patient group (N = 8)
Wrong intervention (N = 3)
Not RCT (N = 12)
Review (N = 6)

64 full-text articles assessed for eligibility

4 studies within 5 articles eligible for inclusion

1 study excluded. No data extracted due to poor study quality

3 studies within 4 articles included in narrative review

3 studies excluded. None had data that could be incorporated into a meta-analysis

0 studies included in quantitative synthesis (meta-analysis)
Included studies
There were four studies (within five articles) eligible for inclusion (Avvisati 1989; Fricke 1991; Gallardo 1983; Shpilberg 1995). The four studies were published between 1989 and 1995. Two were conducted in the USA, one in Israel, and a further one in Italy and the Netherlands. The studies randomised a total of 95 participants (range 8 to 56). See Characteristics of included studies for full details of each study and Table 1 for a comparison between studies.

- Three studies evaluated the effect of tranexamic acid (TXA) therapy in the reduction of bleeding during treatment of acute myeloid leukaemia (Avvisati 1989; Fricke 1991; Shpilberg 1995). One cross-over TXA study (eight patients) was excluded from the outcome analysis because the data were uninterpretable due to major methodological flaws in the study design (see Table 1 for details of the study design) (Fricke 1991). We included data from this study in the 'Risk of bias' assessment.
- One study evaluated the effect of epsilon aminocaproic acid (EACA) for bleeding control during remission induction for acute leukaemia (Gallardo 1983).

In the remainder of this review, these sub-categories will be reported in separate sections.

Tranexamic acid (TXA) versus placebo
There were three studies evaluating this comparison (Avvisati 1989; Fricke 1991; Shpilberg 1995) (Table 1).

Participants
In total 76 patients were randomised to receive TXA or placebo (Table 1). The population characteristics varied between the studies. In Avvisati 1989, the 12 patients randomised were all diagnosed with acute promyelocytic leukaemia (APML) and were all undergoing induction chemotherapy. In Fricke 1991, seven patients had aplastic anaemia (AA) and one patient had myelodysplastic syndrome (MDS); all were out-patients but no other treatments were reported. In Shpilberg 1995, all 56 patients had acute myeloid leukaemia (AML), however, only one of the patients randomised was diagnosed with APML (consolidation group). Thirty-eight of the patients randomised were undergoing induction chemotherapy and 18 were undergoing consolidation chemotherapy.

Intervention
All three studies compared TXA versus placebo (Table 1). In Avvisati 1989, TXA or placebo began at the same time as the antileukaemic therapy (day 1) and lasted for 14 days. In Fricke 1991, all patients served as their own control and, after a four-day trial period to test drug tolerance (followed by a one-week interval without the drug), each patient began a course of either TXA or placebo that lasted for four weeks or until a platelet transfusion was required to control bleeding. In Shpilberg 1995, TXA or placebo was given when the platelet count was less than 20 x 10^9/l or in a falling trend and less than 50 x 10^9/l.

Co-interventions
In Avvisati 1989, platelet transfusions (6 to 8U/m²) were given routinely during the first seven days and additionally for overt haemorrhage, and packed red cells were administered to maintain the haemoglobin concentration above 9.0 g/dl. In Fricke 1991, each patient’s personal physician was permitted to determine the need for platelet transfusion based on “some form of bleeding, such as severe petechiae, blood blisters, and gum or nose bleeding”. No red cell transfusion policy was stated. In Shpilberg 1995, platelet transfusions (4 units/m²) were given irrespective of the count but only when clinically significant bleeding occurred and packed red cells were given to maintain the haemoglobin concentration above 9.0 g/dl.

Outcomes
Efficacy endpoints in Avvisati 1989 were severity of bleeding, thromboembolism, laboratory assessment of fibrinolysis, packed red cell and platelet concentrate transfusion requirement. In Fricke 1991, the endpoints were number of bleeding episodes, severity of bleeding episodes, site of bleeding episodes, red cell and platelet transfusion requirements, and drug side effects. Shpilberg 1995 reported the number of bleeding events and severity of bleeding (using a scoring system), red cell and platelet concentrate transfusion requirement, thromboembolism and adverse events of drug, duration of hospitalisation, duration of significant thrombocytopenia (< 20 x 10^9/l) and days with fever.

Epsilon aminocaproic acid (EACA) versus placebo
There was only one study evaluating this comparison (Gallardo 1983). It was an abstract published in 1983 detailing a randomised two-arm study with patients undergoing remission induction for acute leukaemia.

Participants
In total 19 patients undergoing remission induction for acute leukaemia were randomised to receive EACA or not; 15 with AML and four with acute lymphocytic leukaemia (ALL). One patient...
was not evaluable for unstated reasons, leaving nine patients in each study arm.

**Intervention**

All patients received platelet transfusions (multiple, single donor or HLA-matched) in the event of thrombocytopenia (< 20,000/µl) - this count defined the “days at risk of bleeding”. One arm received EACA (100 mg/kg loading dose and 12 to 24 g/day thereafter in divided doses) with the platelet transfusion whilst the other arm did not.

**Co-interventions**

All patients received platelet transfusions (multiple, single donor or HLA-matched) in the event of thrombocytopenia (< 20,000/µl) - this count defined the "days at risk of bleeding". This study reported no other co-interventions.

**Outcomes**

Outcomes reported included bleeding; either as capillary bleeding (CB; skin, mucous membranes, conjunctivae, nose, guaiac in gastrointestinal (GI) or genitourinary (GU) tract) or major bleeding (MB; nose bleeding requiring posterior packing, gross GI or GU bleeding and central nervous system (CNS) bleeding), monitoring of antifibrinolytic therapy using $^{125}$I fibrinogen plasma clot lysis, platelet transfusion requirement, adverse events of drug and thromboembolism.

**Tranexamic acid versus epsilon aminocaproic acid**

No RCTs that evaluated this comparison were identified.

**Excluded studies**

See Characteristics of excluded studies for further details.

- Twelve studies were not randomised controlled trials.
- Eight studies examined different patient groups.
  - Amar 2003; Byams 2007; Celebi 2006; McConnell 2011; McConnell 2012; Mevio 1983; Movafegh 2011; Yang 2001
- Six studies were reviews.
  - Bates 2011; Breen 2012; Brown 2002; Levy 2005; Marti-Carvajal 2011; Rickles 2007
- Three studies examined a different intervention.
  - Bedirhan 2001; Jeserschek 2003; Kardel 1998

**Risk of bias in included studies**

See Figure 2 and Characteristics of included studies for further details.
Figure 2. 'Risk of bias' summary: review authors’ judgements about each risk of bias item for each included study.

<table>
<thead>
<tr>
<th></th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Blinding of participants and personnel (performance bias)</th>
<th>Blinding of outcome assessment (detection bias)</th>
<th>Incomplete outcome data (attrition bias)</th>
<th>Selective reporting (reporting bias)</th>
<th>Other bias</th>
<th>Protocol deviation balanced?</th>
</tr>
</thead>
</table>
All studies (Avvisati 1989; Fricke 1991; Gallardo 1983; Shpilberg 1995) had some threats to validity. The majority of these threats were due to a lack of detail provided on the specific criteria and we therefore judged them as ‘unclear’ using the Cochrane grading system. However Fricke 1991 had significant flaws in study design which we considered ‘high risk’, including attrition bias, reporting bias and other sources of bias (see Figure 2 and Characteristics of included studies).

**Allocation**

None of the studies reported the method of sequence generation or allocation concealment and all were reported in this review as having an unclear risk of bias.

**Blinding**

We deemed all studies to have an unclear risk of bias (Avvisati 1989; Fricke 1991; Gallardo 1983; Shpilberg 1995). In Avvisati 1989, the risk of performance bias and detection bias were unclear as the article states that attending physicians were blinded to the treatment groups and that bleeding assessments were examined by the same investigator, but it is not stated whether the investigator was one of the attending physicians. In Gallardo 1983, the risk of performance and detection bias was unclear as the abstract did not state whether the investigators and or patients were blinded or not and does not state who carried out the bleeding assessments. In Shpilberg 1995, the threat of performance and detection bias was unclear as although the study states that it was double-blinded, no further details were given as to who was blinded. In Fricke 1991, although it was stated that study was double-blinded, the article states that drug levels were obtained during 38 of the 49 courses. It does not state that the investigators or patients were blinded to this information. It also states that the study defined overall success of TXA in a patient as either five failures of placebo and none of drug or seven failures of placebo and one of drug and defined overall failure of TXA as two failed courses of drug. Sequential courses continued until overall success or failure of TXA could be determined. However, it did not state how this assessment of success or failure was performed without un-blinding study personnel.

**Incomplete outcome data**

There were no missing outcome data in Avvisati 1989, so we deemed the article to have a low risk of attrition bias. We deemed Fricke 1991 to have a high risk of bias - the article states that “three [of eight] patients completed the randomised portion of the study ... five of the eight patients did not complete enough courses to determine the efficacy of the drug”. The two remaining studies (Gallardo 1983; Shpilberg 1995) were deemed to have an unclear risk of bias as there were insufficient data to assess incomplete outcome data.

**Selective reporting**

We deemed two studies to have an unclear risk of bias (Avvisati 1989; Shpilberg 1995) and two studies to have a high risk of bias (Fricke 1991; Gallardo 1983). There were insufficient data to assess the risk of selective reporting (reporting bias) in Avvisati 1989 and in Shpilberg 1995 and we deemed these to have an unclear risk of bias. There was a high risk of reporting bias in two studies (Fricke 1991; Gallardo 1983) In Fricke 1991, one patient died of intracranial haemorrhage four days after starting the first randomised course. Data from this course were not reported. There were two courses of TXA or placebo interrupted in two separate patients; one due to an upper respiratory tract infection and the other in which the patient developed an oesophageal haematoma after starting antibiotic treatment for an infection. Data from these courses were not included in the analysis as the investigators felt that the infection/antibiotic treatment may have compromised haemostasis. Furthermore, in Fricke 1991, the article states that severity of bleeding (as well as number and site) were recorded by the assessor (the patient) but this outcome is not reported in the article. Finally, five of the eight patients were reported as not completing enough sessions to determine the effectiveness of TXA.

In Gallardo 1983, there are data for thromboembolism and death (“no patient died of thrombosis”) but no data given on number episodes of thromboembolism or number of deaths. There are also no data reported on the monitoring of antifibrinolytic therapy using fibrinogen plasma clot lysis. This may have been because the article was an abstract and there was limited space available.

**Other potential sources of bias**

We deemed two studies to have a low risk of bias (Avvisati 1989; Shpilberg 1995), one an unclear risk of bias (Gallardo 1983) and the remaining one a high risk of bias (Fricke 1991). Avvisati 1989 and Shpilberg 1995 seemed to be free of other sources of bias and we deemed them to be at low risk of bias. In Gallardo 1983, the “at risk of bleeding days” were much higher in the EACA group - 158 versus 80 due to more severe thrombocytopenia and more cycles of chemotherapy for refractory disease. There may be bias in the randomisation procedure but the method of randomisation is not stated and we deemed the study overall to have an unclear risk of bias. There were other sources of potential bias in Fricke 1991. The overall success of TXA was defined as either five failures of placebo and none of the drug or seven failures of placebo and one of the
drug and overall failure of TXA was defined as two failed courses of drug. Failure of a course was defined as a patient receiving a platelet transfusion for bleeding during a four-week study period. Patients received a variable number of courses of drug/placebo. The three patients who completed the study received between three (two TXA, one placebo) and nine courses (five TXA, four placebo) of treatment. The five patients who did not complete the study received between zero and 20 courses (10 TXA, 10 placebo) of treatment. Of the three patients who completed the study, two did not have any successful courses of treatment. The third patient had 3/5 successful courses with TXA and 1/4 successful courses with placebo, however this was classified by the study as a failure of TXA (two failed courses with TXA). Interim analysis of the data was therefore performed after each course of treatment for each patient, with completion of the study being biased against TXA (only two failures of TXA are required, whereas five failures of placebo and none of TXA for study to be classified as completed). In Fricke 1991, failure of a course of treatment would be classified in the same way whether patient was on study drug for one day before bleeding or 27 days before bleeding that required treatment with a platelet transfusion. More bleeding episodes seen in the TXA arm may have been due to more days on study drug before bleeding requiring a platelet transfusion. Number of days on study drug before bleeding was not reported for individual courses.

No protocol deviations were commented upon in any of the studies. However, in Fricke 1991, one patient began receiving HLA-matched platelet transfusions two months after enrolment and was kept in the study because these platelet transfusions failed to control bleeding. Definition of failure of a course of treatment for this patient was the need for additional platelet transfusions. It is unclear whether this represented a protocol violation but two other patients were withdrawn from the study after they started to receive HLA-matched platelet transfusions.

Effects of interventions

See: Summary of findings for the main comparison

Antifibrinolytics (lysine analogues) compared to placebo to prevent bleeding in patients with haematological disorders (See Table 2 and Table 3)

Tranexamic acid (TXA) versus placebo

There were three studies evaluating this comparison (Avvisati 1989; Fricke 1991; Shpilberg 1995).

We extracted no data from the Fricke 1991 study due to major methodological problems in the study design. In addition to the high risk of bias in terms of attrition bias, reporting bias and other bias (see text section above, Figure 2 and the Risk of bias in included studies table) there were a variable number of study cycles depending on the results of previous cycles of treatment. All these factors meant that it was impossible to fully understand the data in this trial and we took the decision to not include this trial in the assessment of 'effects of interventions'.

Number, site and severity of bleeding (i.e. any bleeding, clinically significant bleeding, life-threatening bleeding)

Both studies reported bleeding. Avvisati 1989 reported bleeding as a cumulative score in the first observation period (days two to seven), second observation period (days eight to 14) and overall cumulative score. The cumulative score when comparing TXA and placebo in the first, second and overall study periods were 2 versus 31, 1 versus 11, and 3 versus 42, respectively. Shpilberg 1995 reported the mean number of bleeding events per patient.

During induction chemotherapy, the mean number of bleeding events per patient was 6.2 (2.9) versus 4.5 (3.6) for TXA and placebo respectively. During consolidation chemotherapy, there was a statistically significant difference (P < 0.5) comparing TXA with 1.1 (1.4) bleeding events per patient versus 2.6 (2.2) in the placebo arm. There was also a statistically significant difference in the bleeding score during consolidation chemotherapy with 1.3 (1.8) in the TXA arm versus 5.1 (3.6) in the placebo arm.

Thromboembolism (venous and arterial)

Both studies reported thromboembolism but did not distinguish between arterial or venous events. Shpilberg 1995 reported that no thromboembolic events occurred in either group throughout the study. Avvisati 1989 reported that there were no thromboembolic complications and there was no evidence of enhanced thrombin generation (as assessed by thrombin-antithrombin-III complexes). TXA was only given for the first six days out of 14 days of observation because of what the authors described as the “known increase of cerebral thromboembolic disease with prolonged therapy”.

Mortality (all causes)

Neither study reported all-cause mortality.

Mortality (secondary to bleeding)

Only Shpilberg 1995 reported mortality (secondary to bleeding) and stated that there was no fatal bleeding in either group.

Mortality (secondary to thromboembolism)

Neither study reported mortality secondary to thromboembolism.

Laboratory assessment of fibrinolysis

Only Avvisati 1989 reported laboratory assessment of fibrinolysis. There were no statistically significant differences in the coagulation and fibrinolysis indices between the two groups apart from the results for fibrin degradation products The study stated that...
median fibrin degradation products decreased in the TXA arm but increased in the placebo arm during the first week of observation (P < 0.01) (Table 4).

**Number of platelet transfusions**

Both studies reported the number of platelet transfusions. Avvisati 1989 reported that in the first period of observation (days two to seven) 69 units of platelets were transfused in the TXA arm versus 177 units in the placebo arm. In the second period of observation (days eight to 14) 0 units of platelets were transfused in the TXA arm versus 45 units in the placebo arm. Overall, 69 units were transfused in the TXA arm versus 222 units in the placebo arm. During induction chemotherapy in Shpilberg 1995, there was no difference in the mean number of platelet transfusions in the TXA arm (22.1 (13.2)) units versus the placebo arm (23.1 (11.70). However, there was a significant difference (P < 0.05) during consolidation chemotherapy with respect to the mean number of platelet units transfused between the TXA arm (3.7 (4.1)) versus the placebo arm (9.3 (3.3)).

**Number of red cell transfusions**

Both studies reported number of red cell transfusions. Avvisati 1989 reported a reduction in red cell transfusions given to the TXA arm compared to the placebo arm. During the first observation period (day two to seven) 19 units were transfused in the TXA arm compared to 35 units in the placebo arm. In the second observation period (days eight to 14), nine units were transfused versus 21 units. Overall 21 units were transfused in the TXA arm versus 56 units in the placebo arm. During induction, the mean number of transfusions in the TXA arm versus the placebo arm was 7.5 (4.7) versus 7.3 (3.3). During consolidation, the mean number was 4.1 (2.8) units versus 4.1 (3.4) units in the TXA and placebo arms, respectively.

**Adverse events of antifibrinolytic agents**

Avvisati 1989 did not report adverse events of antifibrinolytic agents. Shpilberg 1995 reported that no side effects were observed.

**Adverse events of transfusions (e.g. transfusion reactions, antibody development)**

Neither study reported the adverse events of transfusions.

**Disseminated intravascular coagulation (DIC)**

Neither study reported DIC.

**Quality of life**

Neither study reported quality of life.

**Epsilon aminocaproic acid (EACA) versus placebo**

There was only one study evaluating this comparison (Gallardo 1983). It was a randomised two-arm study published in 1983 involving patients undergoing remission induction for acute leukaemia.

**Number, site and severity of bleeding (i.e. any bleeding, clinically significant bleeding, life-threatening bleeding)**

Gallardo 1983 reported bleeding as the proportion of days at risk of bleeding (defined as where the platelet count was < 20,000/ microlitre). This was 158 days for the group on EACA compared to only 80 for the group on no EACA, but the abstract noted that the patients on EACA had more severe thrombocytopenia and more cycles of chemotherapy for refractory disease. Capillary bleeding (i.e. bleeding in skin, mucous membranes, conjunctivae, nose and guaiac in gastrointestinal (GI) or genitourinary (GU) tract) was present in 31% of days at risk with patients on EACA compared to 50% of patients not receiving EACA (P value not reported). There was no difference in major bleeding (defined as nose bleeding requiring posterior packing, gross GI or GU bleeding and bleeds within the CNS) between the two groups (15% versus 19%) (P value not reported).

**Thromboembolism (venous and arterial)**

There were no reports of thromboembolism although the study stated that no patient died of thrombosis.

**Mortality (all causes)**

The study did not report all-cause mortality.

**Mortality (secondary to bleeding)**

The study did not report mortality secondary to bleeding.

**Mortality (secondary to thromboembolism)**

The study stated that no patient died of thrombosis.

**Laboratory assessment of fibrinolysis**

The study reported that antifibrinolytic therapy was monitored with the I$^{125}$ fibrinogen plasma clot lysis assay although no further data were described regarding this outcome.
Number of platelet transfusions
The study reported that platelet transfusions per days at risk were decreased in the patients on EACA, one every 13.3 versus one every 10.5 days at risk. However, the authors noted that these were not statistically significant (P value not reported). The abstract detailed a projection that the results would achieve statistical significance at a P value of < 0.05 with 25 patients in each group. However, no subsequent study has since been published. It is therefore important to note that there were insufficient patients within this study to show statistical significance for any clinically meaningful true difference.

Number of red cell transfusions
The study did not report the number of red cell transfusions.

Adverse events of antifibrinolytic agents
No specific adverse events were described, although the study stated that side effects were minimal.

Adverse events of transfusions (e.g. transfusion reactions, antibody development)
The study did not report adverse events of transfusions.

DIC
The study did not report DIC.

Quality of life
The study did not report quality of life.

Tranexamic acid versus epsilon aminocaproic acid
No RCTs that evaluated this comparison were identified.

Discussion
The overall aim of this review was to determine the efficacy and safety of antifibrinolytics (lysine analogues) in the prevention of bleeding in patients with haematological disorders. Specifically, we aimed to address the following questions:

i) Do lysine analogues help to prevent bleeding in thrombocytopenic patients with haematological disorders?

ii) Can the number of prophylactic platelet transfusions be minimised?

iii) Do lysine analogues increase the incidence of thromboembolism?

Our primary outcomes were bleeding and the occurrence of thromboembolism. Our secondary outcomes were mortality, laboratory assessment of fibrinolysis, number of platelet transfusions, number of red cell transfusions, adverse events of antifibrinolytic agents, adverse events of transfusions (e.g. transfusion reactions, antibody development), disseminated intravascular coagulation (DIC) and quality of life.

Summary of main results
Only four studies met our inclusion criteria and one of these studies had to be excluded from the assessment of Effects of interventions due to major methodological flaws in its design and a high risk of bias across several criteria. Of the remaining three randomised controlled trials (RCTs), a total of 86 patients were investigated. There were two studies comparing tranexamic acid (TXA) and placebo (Avvisati 1989; Shpilberg 1995) and one study comparing epsilon aminocaproic acid (EACA) with placebo (Gallardo 1983). There were no studies comparing TXA with EACA.

i) Do lysine analogues help to prevent bleeding in thrombocytopenic patients with haematological disorders?
All three studies suggested antifibrinolytics reduced the risk of bleeding, although one study (Shpilberg 1995) only demonstrated this effect in patients undergoing consolidation chemotherapy and not during induction chemotherapy.

ii) Can the number of prophylactic platelet transfusions be minimised?
All three studies reported a reduction in platelet usage. However, in Shpilberg 1995, the effect was only noted for patients undergoing consolidation chemotherapy. This is consistent with the finding that it was only this population who seemed to benefit from both reduced bleeding and a reduced need for platelet transfusions. Gallardo 1983 reported one platelet transfusion every 10.5 days at risk in the placebo arm versus one platelet transfusion every 13.3 days at risk in the EACA arm. However, the authors noted that these data were not statistically significant.

iii) Do lysine analogues increase the incidence of thromboembolism?
Two studies reported the presence or absence of thromboembolism and no events occurred in either of these studies (Avvisati 1989; Shpilberg 1995). It was reported in Gallardo 1983 that no patient died of thrombosis.

Other results
Two of the studies (Avvisati 1989; Shpilberg 1995) reported red blood cell (RBC) transfusion requirements. There was no significant difference between the TXA and placebo arms in one study (Shpilberg 1995) but the other found a significant reduction in RBC usage in the TXA arm (Avvisati 1989).

None of the studies reported on overall (all-cause) mortality. However, one of the studies reported on mortality due to bleeding (Shpilberg 1995) and only one reported on mortality due to...
Thromboembolism (Gallardo 1983); none occurred in either category.

Two studies (Gallardo 1983; Shpilberg 1995) reported on the side effects of antifibrinolytics. Gallardo 1983 stated that the side effects of EACA “were minimal” but did not provide any further detail on this within the abstract. Shpilberg 1995 also reported on side effects of TXA and stated that none were observed.

None of the studies reported on several of our outcomes, these included: adverse events of transfusion, presence or development of DIC, and quality of life.

Overall completeness and applicability of evidence

There are a number of limitations that may affect the strength of any conclusions in this review. Only three small studies were included within this review. Two studies (68 patients) compared TXA with placebo and one study (18 patients) compared EACA with placebo. It was not possible to extract data on outcomes for all trials, and due to the age of all three studies only one author could be located. This author no longer had data available because the trial was conducted over 30 years ago (Gallardo 1983).

Do lysine analogues help to prevent bleeding in thrombocytopenic patients with haematological disorders?

All of the three included studies suggested that bleeding was reduced, although in one study (Shpilberg 1995) this effect was limited to patients undergoing consolidation chemotherapy. The authors suggested that this may have been due to the more complex coagulopathy involved during induction chemotherapy and this may be why there was no appreciable benefit of antifibrinolytics. Clearly, the numbers were small and larger RCTs would be required to support this observation.

Can the number of prophylactic platelet transfusions be minimised?

Again, all studies were suggestive of a role of antifibrinolytics in reducing platelet usage, but it is important to note that in Shpilberg 1995 the effect was only seen in the consolidation group and not in the induction group, and in Gallardo 1983, although the number of platelet transfusions required per days at risk was less for the EACA arm, the results were not statistically significant and greater numbers would be required to achieve this. The authors projected that the results would reach statistical significance at a P value of < 0.05 with 25 patients in each group. However, despite an extensive literature search, no further data were published with larger patient groups.

Do lysine analogues increase the incidence of thromboembolism?

Two studies (68 patients) reported the presence or absence of thromboembolic events and no events occurred in either study (Avvisati 1989; Shpilberg 1995). It was reported in Gallardo 1983 that no patient died of thrombosis but it is unclear whether any non-fatal thromboembolic events occurred at all. Although there is no evidence within these three studies to suggest that there is an increased risk of thromboembolism with antifibrinolytics there are insufficient data to conclude that this risk does not exist.

Other results

None of the studies reported on several of this review’s outcomes, these included: adverse events of transfusion, the presence or development of DIC, and Quality of Life. This highlights the paucity of data in this area.

Quality of the evidence

We assessed the quality of the evidence using the GRADE approach and this was either very low or the outcome had not been reported by any of the studies (Summary of findings for the main comparison). We were unable to gain additional information via direct author contact and therefore could not improve the quality of the data.

One study (Fricke 1991) had significant methodological problems with its design (Risk of bias in included studies and Figure 2). The overall success of TXA was defined as either five failures of placebo and none of the drug, or seven failures of placebo and one of the drug. Overall failure of TXA was defined as two failed courses of the drug. Failure of a course was defined as a patient receiving a platelet transfusion for bleeding during a four-week study period. Patients received a variable number of courses of drug/placebo. The three patients who completed the study received between three (two TXA, one placebo) and nine courses (five TXA, four placebo) of treatment. The five patients who did not complete the study received between zero and 20 courses (10 TXA, 10 placebo) of treatment. Of the three patients who completed the study, two did not have any successful courses of treatment. The third patient had 3/5 successful courses with TXA and 1/4 successful courses with placebo, however this was classified by the study as a failure of TXA (two failed courses with TXA). Interim analysis of the data was therefore performed after each course of treatment for each patient, with completion of the study being biased against TXA (only two failures of TXA are required, whereas five failures of placebo and none of TXA for study to be classified as completed). All of the other three included studies (Avvisati 1989; Gallardo 1983; Shpilberg 1995) had some threats to validity and in most cases this was graded as ‘unclear’ due to lack of detail in the study to determine the level of risk. One of these studies (Gallardo 1983) was at high risk of selective reporting. The data were presented.
in an abstract form and the problem was likely to have been due to limited space. However, important data were omitted, most notably number of episodes of thrombosis since the comment “no patient died of thrombosis” is suggestive of the presence of thrombosis in the study. This is clearly of particular importance when considering the safety of antifibrinolytics when thrombosis is a noted side effect of these agents.

Avisati 1989 appeared to be the study most free of bias with low risk when considering attrition bias and other bias. Other than those mentioned, the other parameters for bias were listed as unclear to due a lack of data to determine risk as high or low.

One negative aspect that all the studies had in common was low sample sizes which reduced their statistical power. This means that even if a clinically meaningful true difference was present it may not be detected due to the small number of patients within each study. This could not be overcome via the use of meta-analysis because the data had been reported in different ways. In one study in particular (Gallardo 1983) the small sample size was insufficient to permit statistical significance for at least one outcome (number of platelet transfusions in each arm).

Comparison to non-randomised trials
Several small non-randomised studies have used TXA or EACA in haematology patients (Bartholomew 1989; Ben-Bassat 1990; Chakrabarti 1998; Dean 1997; Gardner 1980; Garewal 1985; Kalmadi 2006; Schwartz 1986; Wassenaar 2008). However, virtually all of these studies did not have a comparator arm, making it difficult to draw any valid conclusions on the effectiveness and safety of antifibrinolytics. One larger study of TXA in patients with acute promycylocytic leukaemia (APL) used an historical control (Sanz 2010); there was no difference in deaths due to bleeding between those patients who received TXA and those who did not. Death due to bleeding is a rare event and this study may not have had sufficient power to detect a difference. This study (Sanz 2010) did show a statistically significant increase in the number of patients who developed thromboembolic complications. However, because Sanz 2010 used an historical control there may have been other confounding factors including changes to the chemotherapy regime used that could have also affected the number of thromboembolic events.

Potential biases in the review process
There were no clear biases identified in the review process.

The systematic methods of searching, data extraction and result analysis were followed with reference to the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a).

One important consideration was whether our decision not to include Fricke 1991 in the narrative review of the included studies may represent some risk of publication bias. Fricke 1991 was the only study that showed a lack efficacy of the antifibrinolytic (TXA). However, given the methodological flaws and high levels of risk across several criteria as mentioned in Assessment of risk of bias in included studies, it was felt that it should be excluded from the narrative review.

Agreements and disagreements with other studies or reviews
The fact that there were so few RCTs that were suitable for inclusion in our narrative review demonstrates the lack of efficacy and safety data for the use of antifibrinolytics in thrombocytopenic haematology patients.

Comparison to other systematic reviews
To our knowledge, there are no other systematic reviews examining this topic.
REFERENCES

References to studies included in this review

Avvisati 1989 [published data only]

Fricke 1991 [published data only]

Gallardo 1983 [published data only]

Shpilberg 1995 [published data only]


References to studies excluded from this review

Amar 2003 [published data only]

Bartholomew 1989 [published data only]

Bates 2011 [published data only]

Bedirhan 2001 [published data only]

Ben-Bassat 1990 [published data only]

Breen 2012 [published data only]

Brown 2002 [published data only]

Byams 2007 [published data only]

Cattan 1963 [published data only]

Celebi 2006 [published data only]

Chakrabarti 1998 [published data only]

Dean 1997 [published data only]

Fossa 1978 [published data only]

Gardner 1980 [published data only]

Garewal 1985 [published data only]

Jeserschek 2003 [published data only]

Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)

Kalmadi 2006 [published data only]

Katzel 1998 [published data only]

Levy 2005 [published data only]

Marti-Carvajal 2011 [published data only]

McConnell 2011 [published data only]

McConnell 2012 [published data only]

Movafegh 2011 [published data only]

Rickles 2007 [published data only]

Sanz 2010 [published data only]

Schwartz 1986 [published data only]

Wassenaar 2008 [published data only]

Yang 2001 [published data only]

Additional references

BCSH 2003

Bolton-Maggs 2012

Cameron 2007

Deeks 2011

Faught 1998

Fergusson 2008

Franchini 2010
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)

**Popovsky 1985**

**Prentice 1980**

**Roberts 2011**

**Roos 2008**

**Sawamura 2009**

**Schünemann 2011**

**Shakur 2010**

**Slichter 2005**

**Slichter 2010**

**Sterne 2011**

**Tzortzopoulou 2008**

* Indicates the major publication for the study.
Characteristics of included studies  [ordered by study ID]

Avvisati 1989

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Parallel RCT; 2 centres (Italy and Netherlands). Enrolment period not stated</td>
</tr>
</tbody>
</table>
| **Participants**| **Inclusion criteria:** patients with newly diagnosed APL who met the following criteria: age 15 to 60 yrs; ventricular ejection fraction > 50%; serum alanine aminotransferase (ALT) < 4 x upper limit of normal; creatinine < 177 µmol/l  
**Exclusion criteria:** not stated  
**Arm 1 N = 6 (APL N = 6)**  
**Arm 2 N = 6 (APL N = 6)** |
| **Interventions**| Comparison between TXA and placebo  
**Arm 1 TXA (2 g given as a continuous infusion every 8 h for the first 6 days of antileukaemic treatment)**  
**Arm 2 Placebo (equal volume of 5% glucose)**  
**RBC transfusion thresholds:** packed red cells given to maintain Hb > 9.0 g/dl  
**Platelet transfusion threshold:** 6 to 8 U/m² (source not stated) routinely given during first 7 days and additionally for overt haemorrhage  
Packed red cells and additional platelet concentrates given at the discretion of the attending physician |
| **Outcomes**    | Main or primary outcome not stated  
**Outcomes reported:**  
- Severity of bleeding  
- Thromboembolism  
- Laboratory assessment of fibrinolysis  
- Packed red cell transfusion requirement  
- Platelet concentrate transfusion requirement  
**Number of days patients from both arms on study:** 14 |
| **Notes**       | Patients randomised at: not reported  
**Follow-up of patients:** for 14 days from start of antileukaemic treatment  
**Stopping guidelines:** not reported |

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Patients were randomised to either TXA or placebo. The article does not state how patients were randomised</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
</tbody>
</table>
### Avvisati 1989  *(Continued)*

<table>
<thead>
<tr>
<th>Source</th>
<th>Methods</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>The article states that “Patients and attending physicians were blinded to the treatment groups” and that bleeding assessments were examined by the same investigator but it is not clear whether the investigator was one of the attending physicians</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>“Each patient was examined daily by the same investigator (G.A.) for clinically manifest haemorrhage during the entire study of 14 days”. Unclear whether G.A. was blinded to the treatment groups</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>No missing outcome data</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>The article states that their efficacy endpoints were “severity of bleeding” and the packed red cell and platelet concentrate transfusion requirement but also reports outcome data for laboratory assessment of coagulation and fibrinolysis. It also states that there were no episodes of thromboembolism. We would be concerned as to what other outcomes were measured and not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>The study seemed to be free of other sources of bias</td>
</tr>
<tr>
<td>Protocol deviation balanced?</td>
<td>Unclear risk</td>
<td>Protocol deviations or violations were not commented on</td>
</tr>
</tbody>
</table>

### Fricke 1991

<table>
<thead>
<tr>
<th>Source</th>
<th>Methods</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Cross-over RCT. USA. Enrolment period and centres not stated</td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td><strong>Inclusion criteria:</strong> patients with amegakaryocytic thrombocytopenia who met the following criteria: platelet count &lt; 20,000/microlitre (&lt; 20 x 10⁹/l) with no immediate prospect of recovery and absent/rare megakaryocytes in the bone marrow aspirate/biopsy; at least 1 bleeding episode per month (excluding skin bleeding); a history of platelet transfusions for such bleeding episodes</td>
<td><strong>Exclusion criteria:</strong> patients who had any of the following: active bleeding from an anatomical lesion (e.g. peptic ulcer); personal/family history of hypercoagulopathy; pregnancy; DIC; liver failure; personal history of a congenital bleeding disorder</td>
</tr>
<tr>
<td></td>
<td><strong>Arms</strong> (cross-over RCT): N = 8 (aplastic anaemia N = 7; myelodysplastic syndrome N = 1)</td>
<td></td>
</tr>
</tbody>
</table>
**Interventions**

<table>
<thead>
<tr>
<th>Arm 1</th>
<th>TXA (20 mg/kg) 3 x daily for 4 weeks or until a platelet transfusion was required to control bleeding. Followed by a 1-week rest period. Placebo (equivalent number of identical placebo tablets) for 4 weeks or until a platelet transfusion was required to control bleeding. Followed by a 1-week rest period. The method of allocating the randomised patients to further courses of TXA or placebo was not stated.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm 2</td>
<td>Placebo (equivalent number of identical placebo tablets) for 4 weeks or until a platelet transfusion was required to control bleeding. Followed by a 1-week rest period. TXA (20 mg/kg) 3 x daily for 4 weeks or until a platelet transfusion was required to control bleeding. Followed by a 1-week rest period. The method of allocating the randomised patients to further courses of TXA or placebo was not stated. Further cycles of TXA and placebo were repeated until TXA was deemed a success or a failure.</td>
</tr>
</tbody>
</table>

**RBC transfusion thresholds:** not stated  
**Platelet transfusion thresholds:** platelets (dose and source not stated) given in the event of bleeding as each patient’s personal physician deemed necessary.

**Outcomes**

- Main or primary outcome not stated  
- **Outcomes reported**  
  - Number of bleeding episodes  
  - Severity of bleeding episodes  
  - Site of bleeding episodes  
  - Platelet transfusion requirement  
  - Red cell transfusion requirement  
  - Drug side effects  

**Number of days patients on study:** not stated  
Defined overall success of TXA in a patient as either 5 failures of placebo and none of drug or 7 failures of placebo and 1 of drug. Defined overall failure of TXA as 2 failed courses of drug. Sequential courses continued until overall success or failure of TXA could be determined.

**Notes**

- **Patients randomised at:** not reported  
- **Follow-up of patients:** not reported  
- **Stopping guidelines:** not reported

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>States that patients were randomised but does not state the mechanism of randomisation. Nor does it state whether they were re-randomised after the initial 2 courses of TXA and placebo or what other method was used to allocate them to successive courses of TXA or placebo.</td>
</tr>
<tr>
<td>Study</td>
<td>Allocation concealment (selection bias)</td>
<td>Blinding of participants and personnel (performance bias)</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>States that patients were randomised but does not state the mechanism of allocation</td>
<td>States that study was double-blinded (and the interventions were identical) However, the article states that drug levels were obtained during 38 of the 49 courses. It does not state that the investigators or patients were blinded to this information during the study. &quot;Plasma tranexamic acid levels were taken weekly and before each platelet transfusion, if possible&quot; It also states that the study defined overall success of TXA in a patient as either 5 failures of placebo and none of drug or 7 failures of placebo and 1 of drug. Defined overall failure of TXA as 2 failed courses of drug. Sequential courses continued until overall success or failure of TXA could be determined. However, it did not state how this assessment of success or failure was performed without unblinding study personnel It is unlikely that patients were informed of these results and therefore blinding of participants is assumed to be at low risk of bias. However, it is not clear that study personnel were not informed of the results and therefore overall risk of bias was classified as unclear.</td>
<td>States that study was double-blinded (and the interventions were identical) However, the article states that drug levels were obtained during 38 of the 49 courses. It does not state that the outcome assessors were blinded to this information during the study. &quot;Plasma tranexamic acid levels were taken weekly and before each platelet transfusion, if possible&quot; It also states that the study defined overall success of TXA in a patient as either 5 failures of placebo and none of drug or 7 failures of placebo and 1 of drug. Defined overall failure of TXA as 2 failed courses of drug. Sequential courses continued until overall success or failure of TXA could be determined. However, it did not state how this assessment of success or failure was performed without unblinding study personnel It is unlikely that patients were informed of these results and therefore blinding of participants is assumed to be at low risk of bias. However, it is not clear that study personnel were not informed of the results and therefore overall risk of bias was classified as unclear.</td>
</tr>
<tr>
<td>Source: Fricke 1991 (Continued)</td>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
</tr>
</tbody>
</table>
| | Other bias | High risk | One patient began receiving HLA-matched platelet transfusions 2 months after enrolment and was kept in the study as these transfusions did not completely control the bleeding. This creates bias as the other patients were deemed to have “failed” the course if bleeding necessitating platelet transfusions occurred. 2 other patients were withdrawn after they started to receive HLA-matched platelet transfusions. The overall success of TXA was defined as either 5 failures of placebo and none of the drug or 7 failures of placebo and 1 of the drug. Overall failure of TXA was defined as 2 failed courses of the drug. Failure of a course was defined as a patient receiving a platelet transfusion for bleeding during a 4-week study period. Patients received a variable number of courses of drug/placebo. The 3 patients who completed the study received between 3 (2 TXA, 1 placebo) and 29
9 courses (5 TXA, 4 placebo) of treatment. The 5 patients who did not complete the study received between 0 and 20 courses (10 TXA, 10 placebo) of treatment. Of the 3 patients who completed the study, 2 did not have any successful courses of treatment. The third patient had 3/5 successful courses with TXA and 1/4 successful courses with placebo, however this was classified by the study as a failure of TXA (2 failed courses with TXA).

Failure of a course of treatment would be classified in the same way whether patient was on study drug for 1 day before bleeding or 27 days before bleeding that required treatment with a platelet transfusion. More bleeding episodes seen in TXA arm may have been due to more days on study before bleeding requiring a platelet transfusion. Number of days on study drug before bleeding was not reported for individual courses.

**Fricke 1991 (Continued)**

| Protocol deviation balanced? | Unclear risk | Insufficient information to determine |

**Gallardo 1983**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Parallel RCT. Abstract. Single centre: USA. Enrolment period not stated</th>
</tr>
</thead>
</table>
| Participants | **Inclusion criteria:** patients undergoing remission induction for acute leukaemia. No other inclusion criteria stated  
**Exclusion criteria:** not stated  
N = 19 were eligible. N = 9 in each arm (AML N = 15; ALL N = 4). N = 1 was not evaluable (reason not stated). Distribution of subtypes in to each arm not stated  
Arm 1 N = 9  
Arm 2 N = 9 |
| Interventions | Comparison between EACA therapy and no EACA therapy.  
**Arm 1** N = 9 (to receive EACA 100 mg/kg loading dose and 12 to 24 g/day in divided doses)  
**Arm 2** N = 9 (did not receive EACA)  
**RBC transfusion threshold:** not stated  
**Platelet transfusion threshold:** patients in both arms were administered platelet transfusion (dose and source not stated) when platelet count < 20,000/microlitre. This threshold defined the “days at risk of bleeding” |
| Outcomes | Main or primary outcomes not stated.  
Outcomes reported:  
- Bleeding; either as capillary bleeding (CB; skin, mucous membranes,
conjunctivae, nose, guaiac in GI or GU tract) or major bleeding (MB; nose bleeding requiring posterior packing, gross GI or GU bleeding and CNS bleeding

- Monitoring of antifibrinolytic therapy using $^{125}$I fibrinogen plasma clot lysis
- Platelet transfusion requirement
- Adverse events of antifibrinolytic
- Thromboembolism

**Number of days patients on study:** not reported

**Notes**

- **Patients randomised at:** not reported
- **Follow-up of patients:** not reported
- **Stopping guidelines:** not reported

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit a judgement of 'high' or 'low' risk</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit a judgement of 'high' or 'low' risk</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information to permit a judgement of 'high' or 'low' risk. The abstract does not state whether investigators and patients were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information to permit a judgement of 'high' or 'low' risk. The abstract does not state who carried out the bleeding assessments</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information to permit a judgement of 'high' or 'low' risk</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>There are data for thromboembolism and death (&quot;no patient died of thrombosis&quot;) but no data given on number episodes of thromboembolism or number of deaths. No data reported monitoring of antifibrinolytic therapy using $^{125}$I fibrinogen plasma clot lysis</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>The &quot;at risk of bleeding days&quot; were much higher in the EACA group - 158 vs. 80 due to more severe thrombocytopenia and more cycles of chemotherapy for refractory disease. There may be bias in the randomisation procedure but method of randomi-</td>
</tr>
</tbody>
</table>
### Shpilberg 1995

#### Methods
Parallel RCT. Enrolment period 1990 to 1992. 2 centres (Israel)

#### Participants
- **Inclusion criteria**: de novo AML. All ages.  
- **Exclusion criteria**: laboratory signs of DIC; recent history of a thromboembolic event; clinical evidence or suspicion of thromboembolism

There were 2 parts to the study. The first part investigated patients undergoing induction chemotherapy. The second part investigated patients undergoing consolidation chemotherapy.

- **Induction chemotherapy**: N = 38 (FAB M1 N = 5; FAB M2 N = 8; FAB M4 N = 25)  
  - Arm 1 N = 16 (FAB M1 N = 2; FAB M2 N = 2; FAB M4 N = 12)  
  - Arm 2 N = 22 (FAB M1 N = 3; FAB M2 N = 6; FAB M4 N = 13)

- **Consolidation chemotherapy**: N = 18 (FAB M2 = 8; FAB M3 = 1; FAB M4 = 9)  
  - Arm 1 N = 10 (FAB M2 N = 5; FAB M3 N = 1; FAB M4 N = 4)  
  - Arm 2 N = 8 (FAB M2 N = 3; FAB M4 N = 5)

#### Interventions
Comparison between TXA and placebo in patients receiving (i) induction chemotherapy and (ii) consolidation chemotherapy. Both parts of the investigation had the same intervention.

- **Arm 1 TXA 1 g every 6 hours**  
- **Arm 2** Identically appearing placebo

- **RBC transfusion threshold**: administered to maintain > 9 g/dl
- **Platelet transfusion threshold**: patients in both arms were administered platelet transfusions. (Random donor pooled; 4 units/m²) in the event of clinically significant bleeding, irrespective of platelet count

#### Outcomes
Main or primary outcomes not stated  
Outcomes reported:
- Number of bleeding events and severity of bleeding (using a scoring system)
- Platelet concentrate transfusion requirement
- Red cell transfusion requirement
- Thromboembolism
- Adverse events of drug
- Duration of hospitalisation
- Duration of significant thrombocytopenia (< 20 x 10⁹/l)
- Days with fever

- **Number of days patients on study**: not stated

#### Notes
- **Patients randomised at**: not reported  
- **Follow-up of patients**: not reported  
- **Stopping guidelines**: not reported

---

**Gallardo 1983** *(Continued)*

<table>
<thead>
<tr>
<th>Protocol deviation balanced?</th>
<th>Unclear risk</th>
<th>Protocol deviations or violations were not commented on</th>
</tr>
</thead>
</table>

---

**Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)**  
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Study states that the trial was randomised but no further details are given as to how this was done</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Study states that the trial was randomised but no further details are given as to how this was done</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Study states that the trial was double-blind but no further details are given as to who was blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Study states that the patients were carefully examined daily by one of the investigators. The trial was double-blind but no further details are given as to who was blinded</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient data to assess</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient data to assess</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>The study seemed to be free of other forms of bias</td>
</tr>
<tr>
<td>Protocol deviation balanced?</td>
<td>Unclear risk</td>
<td>Insufficient information to determine</td>
</tr>
</tbody>
</table>

ALL: acute lymphocytic leukaemia  
AML: acute myeloid leukaemia  
APL: acute promyelocytic leukaemia  
CNS: central nervous system  
DIC: disseminated intravascular coagulation  
EACA: epsilon aminocaproic acid  
FAB: French American British Classification  
GI: gastrointestinal  
GU: genitourinary  
QoL: quality of life  
RBC: red blood cells  
RCT: randomised controlled trial  
TXA: tranexamic acid
### Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amar 2003</td>
<td>Wrong patient group - a randomised controlled trial examining the usefulness of antifibrinolytic therapy in patients with non-haematological malignancy undergoing major orthopaedic surgery</td>
</tr>
<tr>
<td>Bartholomew 1989</td>
<td>Not a RCT - a non-randomised controlled trial on the control of bleeding in patients with immune and non-immune thrombocytopenia with aminocaproic acid</td>
</tr>
<tr>
<td>Bates 2011</td>
<td>Review</td>
</tr>
<tr>
<td>Bedirhan 2001</td>
<td>Wrong intervention - a randomised controlled trial investigating the use of aprotinin in postoperative bleeding and the need for blood products in thoracic surgery</td>
</tr>
<tr>
<td>Ben-Bassat 1990</td>
<td>Not an RCT - non-randomised and non-controlled study of tranexamic acid therapy in acute myeloid leukaemia</td>
</tr>
<tr>
<td>Breen 2012</td>
<td>Review</td>
</tr>
<tr>
<td>Brown 2002</td>
<td>Review</td>
</tr>
<tr>
<td>Byams 2007</td>
<td>Wrong patient group - a cross-over study evaluating the use of desmopressin and tranexamic acid in women with menorrhagia</td>
</tr>
<tr>
<td>Cattan 1963</td>
<td>Not an RCT - non-randomised study of EACA in patients with thrombocytopenia</td>
</tr>
<tr>
<td>Celebi 2006</td>
<td>Wrong patient group - a randomised, double-blind prospective study that examined the role of antifibrinolytic agents in gynaecologic cancer surgery</td>
</tr>
<tr>
<td>Chakrabarti 1998</td>
<td>Not an RCT - non-randomised and non-controlled trial of EACA in patients with acute leukaemia</td>
</tr>
<tr>
<td>Dean 1997</td>
<td>Not an RCT - non-randomised and non-controlled trial of EACA and TXA for cancer-associated bleeding problems</td>
</tr>
<tr>
<td>Fossa 1978</td>
<td>Not an RCT - non-randomised, controlled pilot study on the effect of TXA in patients being treated for various advanced malignancies</td>
</tr>
<tr>
<td>Gardner 1980</td>
<td>Not an RCT - a series of cases of patients with amegakaryocytic thrombocytopenia treated with EACA to control bleeding</td>
</tr>
<tr>
<td>Garewal 1985</td>
<td>Not an RCT - non-randomised and non-controlled trial of EACA for the control of bleeding in thrombocytopenic patients</td>
</tr>
<tr>
<td>Jesenschek 2003</td>
<td>Wrong intervention - a randomised controlled trial examining the role of high-dose aprotinin in the reduction of bleeding in major orthopaedic surgery</td>
</tr>
<tr>
<td>Kalmadi 2006</td>
<td>Not a RCT - retrospective study of the effect of EACA on transfusion requirements in patients with thrombocytopenic haemorrhage</td>
</tr>
<tr>
<td>Author Year</td>
<td>Summary</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Katzel 1998</td>
<td>Wrong intervention - a prospective, controlled, double-blind pilot study examining the role of aprotinin during thoracic surgery for malignant lung disease</td>
</tr>
<tr>
<td>Levy 2005</td>
<td>Review</td>
</tr>
<tr>
<td>Marti-Carvajal 2011</td>
<td>Review</td>
</tr>
<tr>
<td>McConnell 2011</td>
<td>Wrong patient group - a randomised controlled trial examining the reduction of blood loss in primary hip arthroplasty with tranexamic acid fibrin spray</td>
</tr>
<tr>
<td>McConnell 2012</td>
<td>Wrong patient group - a randomised controlled trial examining the reduction of blood loss in primary knee arthroplasty with tranexamic acid fibrin spray</td>
</tr>
<tr>
<td>Mevio 1983</td>
<td>Wrong patient group - a double-blind study examining the role of tranexamic acid in the prevention of radiomucositis in head and neck cancer patients submitted for radiotherapy</td>
</tr>
<tr>
<td>Movafegh 2011</td>
<td>Wrong patient group - a randomised, double-blind study examining the effect of intravenous tranexamic acid on blood loss during and after caesarian delivery</td>
</tr>
<tr>
<td>Rickles 2007</td>
<td>Review</td>
</tr>
<tr>
<td>Sanz 2010</td>
<td>Not an RCT - non-randomised with historical control evaluating the use of tranexamic acid in patients with promyelocytic leukaemia</td>
</tr>
<tr>
<td>Schwartz 1986</td>
<td>Not an RCT - a non-randomised, non-controlled trial of the effect of EACA in patients with acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency</td>
</tr>
<tr>
<td>Wassenaar 2008</td>
<td>Not an RCT - a retrospective study of the use of EACA in patients with acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency</td>
</tr>
<tr>
<td>Yang 2001</td>
<td>Wrong patient group - a randomised, comparative trial examining the efficacy of tranexamic acid in reducing post-partum blood loss in primigravid women</td>
</tr>
</tbody>
</table>

EACA: epsilon aminocaproic acid  
RCT: randomised controlled trial  
TXA: tranexamic acid
**DATA AND ANALYSES**

This review has no analyses.

**ADDITIONAL TABLES**

Table 1. Study characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>No. of patients</th>
<th>No. of patients receiving antifibrinolytic</th>
<th>No. of patients platelet refractory/alloimmunisation</th>
<th>Diagnosis of patients</th>
<th>Treatment of underlying disease</th>
<th>Antifibrinolytic dose</th>
<th>Antifibrinolytic frequency</th>
<th>Antifibrinolytic route</th>
<th>Treatment started</th>
<th>Treatment stopped</th>
<th>Platelets given</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tranexamic acid studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avvisati 1989</td>
<td>RCT</td>
<td>12</td>
<td>6</td>
<td>NR</td>
<td>APL</td>
<td>Chemo</td>
<td>2 g</td>
<td>8-hourly</td>
<td>IV in 500 ml 5% glucose</td>
<td>1st day of antileukaemic Rx</td>
<td>After 6 days</td>
<td>Prophylactic</td>
</tr>
<tr>
<td>Fricke 1991</td>
<td>RCT/Crossover</td>
<td>8</td>
<td>Only 3 completed study</td>
<td>At least 3</td>
<td>7 AA</td>
<td>1 MDS</td>
<td>NR</td>
<td>20 mg/kg</td>
<td>Oral</td>
<td>After 4-day trial period to assess drug tolerance</td>
<td>Successful 4/52 courses or until grade 2 bleeding</td>
<td>Therapeutic</td>
</tr>
<tr>
<td>Shpilberg 1995</td>
<td>RCT</td>
<td>56</td>
<td>26</td>
<td>NR</td>
<td>AML induction 18 consolidation</td>
<td>Chemo</td>
<td>1 g</td>
<td>6-hourly</td>
<td>Oral</td>
<td>Platelets &lt; 20 or rapidly falling and &lt; 50</td>
<td>Platelet count &gt; 20 x 10⁹/l</td>
<td>Therapeutic</td>
</tr>
<tr>
<td><strong>EACA studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallardo 1983</td>
<td>RCT</td>
<td>19</td>
<td>9</td>
<td>NR</td>
<td>AML 4 ALL (1 patient not)</td>
<td>Chemo</td>
<td>Loading dose 100 mg/kg</td>
<td>12 to 24</td>
<td>NR</td>
<td>Platelet count &lt; 20 x 10⁹/l</td>
<td>Platelet count ≥ 20 x 10⁹/l</td>
<td>Platelet count &lt; 20 x 10⁹/l</td>
</tr>
</tbody>
</table>
Table 1. Study characteristics (Continued)

|----------------------|---------------------------------|-----------------------------|-----------------------------------|------------|--------------------------------|----------------|-----------------------------|-----------------|-----------------------------|---------------------|

Table 2. Results of studies (primary outcomes of review)

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Number of patients</th>
<th>Type of patients</th>
<th>Number, site and severity of bleeding</th>
<th>Thromboembolism (venous and arterial)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tranexamic acid studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avvisati 1989</td>
<td>RCT</td>
<td>12</td>
<td>APL</td>
<td>Cumulative haemorrhagic scores</td>
<td>No thromboembolic events observed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TXA 3 C 42</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(P = 0.0045)</td>
<td></td>
</tr>
<tr>
<td>Shpilberg 1995</td>
<td>RCT</td>
<td>56</td>
<td>AML</td>
<td>Mean number of bleeding events per patient:</td>
<td>No thromboembolic events observed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Induction TXA 6.2 ± 2.9 C 4.5 ± 3.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Consolidation TXA 1.1 ± 1.4 C 2.6 ± 2.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(P &lt; 0.05)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cumulative haemorrhagic scores</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Induction TXA 8.3 ± 4.8 C 5.6 ± 4.8</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Consolidation TXA 1.3 ± 1.8 C 5.1 ± 3.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(P &lt; 0.05)</td>
<td></td>
</tr>
<tr>
<td><strong>EACA Studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallardo 1983</td>
<td>RCT</td>
<td>19</td>
<td>15 AML</td>
<td>Capillary bleeding: EACA 31% of days at risk</td>
<td>No deaths due to thromboembolic disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 ALL</td>
<td>Placebo 50% of</td>
<td></td>
</tr>
</tbody>
</table>

Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review)  
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Results of studies (primary outcomes of review)  
(Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Number of patients</th>
<th>Type of patients</th>
<th>Mortality (all causes)</th>
<th>Mortality (secondary to bleeding)</th>
<th>Mortality (secondary to thromboembolism)</th>
<th>Laboratory assessment of fibrinolysis</th>
<th>Number of platelet transfusions</th>
<th>Number of red cell transfusions</th>
<th>Adverse events of antifibrinolytic agents</th>
<th>Adverse events of transfusions (e.g. transfusion reactions, antibody development)</th>
<th>DIC</th>
<th>QoL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avvisati 1989</td>
<td>RCT</td>
<td>12</td>
<td>APL</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>No difference in the coagulation and fibrinolysis indices</td>
<td>Platelet Tx TXA = 45 Tx C = 246 Tx P = 0.045</td>
<td>Reduction in overall RBC transfusions required in TXA</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

¶ Days at risk defined as days when platelet count fewer than $20 \times 10^9/l$.
+ Capillary bleeding defined as bleeding in skin, mucous membranes, conjunctivae, nose and guaiac in gastrointestinal or genitourinary tract.
‡ Major bleeding defined as nose bleeding requiring posterior packing, gross gastrointestinal or genitourinary tract bleeding and central nervous system bleeding.
ALL: acute lymphocytic leukaemia
AML: acute myeloid leukaemia
APL: acute promyelocytic leukaemia
C: control
EACA: epsilon aminocaproic acid
RCT: randomised controlled trial
TXA: tranexamic acid

Table 3. Results of studies (secondary outcomes of review)

Tranexamic acid studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Number of patients</th>
<th>Type of patients</th>
<th>Mortality (all causes)</th>
<th>Adverse events of transfusions (e.g. transfusion reactions, antibody development)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avvisati 1989</td>
<td>RCT</td>
<td>12</td>
<td>APL</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>
Table 3. Results of studies (secondary outcomes of review)  

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>n</th>
<th>AML or TXA induction</th>
<th>NR</th>
<th>No fatal bleeding in either group</th>
<th>NR</th>
<th>Induction (units)</th>
<th>NR</th>
<th>No reduction RBC transfusion requirements</th>
<th>NR</th>
<th>No side effects were observed</th>
<th>NR</th>
<th>NR</th>
<th>NR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shpilberg 1995</td>
<td>RCT</td>
<td>56</td>
<td>AML 38 induction</td>
<td>NR</td>
<td>No fatal bleeding in either group</td>
<td>NR</td>
<td>TXA 22.1 ± 13.2</td>
<td>C 23.1 ± 11.7</td>
<td>Consol 3.7 ± 4.1</td>
<td>C 9.3 ± 3.3 (P &lt; 0.05)</td>
<td>TXA 7.5 ± 4.7</td>
<td>C 7.3 ± 3.3</td>
<td>TXA 4.1 ± 2.8</td>
<td>C 4.1 ± 3.4</td>
</tr>
</tbody>
</table>

EACA studies
Table 3. Results of studies (secondary outcomes of review)  
(Continued)

<table>
<thead>
<tr>
<th>Gal-</th>
<th>RCT</th>
<th>15</th>
<th>NR</th>
<th>NR</th>
<th>No patient died of thrombosis</th>
<th>Monitored with the I125 fibrinogen plasma clot lysis assay but no further data described</th>
<th>EACA 1 every 13.3 days at risk</th>
<th>NR</th>
<th>Side effects were stated as minimal</th>
<th>NR</th>
<th>NR</th>
<th>NR</th>
</tr>
</thead>
<tbody>
<tr>
<td>lardo</td>
<td>RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Blood coagulation tests were prothrombin time, activated partial thromboplastin time, fibrinogen, FDP, antithrombin III activity, thrombin-antithrombin III complexes, protein C activity and α2-antiplasmin. These were carried out daily for the first 10 days.

Days at risk defined as days when platelet count fewer than 20 x 10⁹/l.

Capillary bleeding defined as bleeding in skin, mucous membranes, conjunctivae, nose and guaiac in GI or GU tract.

Major bleeding defined as nose bleeding requiring posterior packing, gross gastrointestinal or genitourinary tract bleeding and central nervous system bleeding.

ALL: acute lymphocytic leukaemia
AML: acute myeloid leukaemia
APL: acute promyelocytic leukaemia
C: control
DIC: intravascular coagulation
EACA: epsilon aminocaproic acid
FDPs: fibrin degradation products
GI: gastrointestinal
GU: genitourinary
QoL: quality of life
NR: not reported
RBC: red blood cell
RCT: randomised controlled trial
TXA: tranexamic acid
Tx: transfusion

Table 4. Laboratory assessment of fibrinolysis - Avvisati 1989

<table>
<thead>
<tr>
<th>Coagulation factors</th>
<th>Timing</th>
<th>Treatment groups</th>
<th>Median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Traxexam acid</td>
<td>Placebo</td>
</tr>
<tr>
<td>Fibrinogen (mg/dl)</td>
<td>Baseline</td>
<td>80 (55 to 395)</td>
<td>70 (50 to 190)</td>
</tr>
<tr>
<td>Table 4. Laboratory assessment of fibrinolysis - Avvisati 1989 (Continued)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Thrombin-antithrombin complex (ng/ml)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 3</td>
<td>55 (20 to 125)</td>
<td>62 (45 to 150)</td>
<td></td>
</tr>
<tr>
<td>Day 5</td>
<td>53 (35 to 80)</td>
<td>78 (36 to 150)</td>
<td></td>
</tr>
<tr>
<td>Day 7</td>
<td>60 (50 to 65)</td>
<td>85 (17 to 160)</td>
<td></td>
</tr>
<tr>
<td><strong>α₂-antiplasmin (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>32 (4 to 58)</td>
<td>22 (15 to 26)</td>
<td></td>
</tr>
<tr>
<td>Day 3</td>
<td>50 (20 to 100)</td>
<td>22 (11 to 52)</td>
<td></td>
</tr>
<tr>
<td>Day 5</td>
<td>41 (5 to 51)</td>
<td>17 (5 to 34)</td>
<td></td>
</tr>
<tr>
<td>Day 7</td>
<td>10 (5 to 31)</td>
<td>21 (3 to 37)</td>
<td></td>
</tr>
<tr>
<td><strong>Fibrin/fibrinogen degradation products (µg/dl)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>40 (10 to 80)</td>
<td>80 (40 to 160)</td>
<td></td>
</tr>
<tr>
<td>Day 3</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Day 5</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Day 7</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
</tbody>
</table>

NR: not reported
Appendix 1. CENTRAL search strategy

#1 MeSH descriptor Antifibrinolytic Agents, this term only
#2 MeSH descriptor Tranexamic Acid, this term only
#3 MeSH descriptor Aminocaproic Acids explode all trees
#4 (antifibrinolytic* or anti fibrinolytic* or antiplasmin* or plasmin inhibitor* or tranexamic or cyclohexanecarboxylic acid* or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or kabi 2161 or transamin or exacyl or anitoff or spotof or cyklokapron or ugurol or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amcha or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanecarboxylic acid or amstat or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyclokapron or cyklokapron or hexacapron or hexakapron or TXA)
#5 (Agretax or Bio-Stat or Capiloc or Capitrax or Clip Inj or Clot-XL or Clotawin-T or Cymin or Dubratran or Examic or Existat or Extam or Fibrin or Fibrinogen or Hemostat or Monix or Monitex or Nestran or Nexamin or Nexi-500 or Nexeon or Rheonex or Sylstep TX or Synostar or T-nex or T-Stat or T Stat or Tannic or Tansyl-T or Texakind or Texanis or Texapar or Thams or Thams or Tonopan or Traklot or Traxin or Traxin or Transce or Tranex or Tranexa or Tranfib or Tranlok or Transtat or Transys or Transx or Traspor or Traxame or Traxin or Trim Inj or Tx-1000 or Tx 500 or Wistran or X-Tran or Xamic)
#6 ((aminocaproic or aminacaproic or aminohexanoic or aminohexanoic or epsilon-aminoacaproic or E-aminocaproic or amino caproic or amino-n-hexanoic) NEAR/2 acid*)
#7 (epsikapron or cy-116 or cy116 or epsamon or amicar or acikaprin or acikaprin or caprocin or caprocin or caprolisin or caprolisin or caprolisin or capromol or hemocaprol or caproamin or EACA or caprolest or caprolene or hexalene or hamostat or hemocid)
#8 (cl 10304 or ecapron or ekaprol or epsilcapron or epsilon amino caproate or epsilon aminoacaproate or epsilonaminocaproic or ethaaminocaproic or ethaaminocaproic or emacaprol or hepin or icles or jdr177or neocaprol or nsc26154 or rachostyptan)
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 MeSH descriptor Hematologic Neoplasms explode all trees
#11 MeSH descriptor Leukemia explode all trees
#12 MeSH descriptor Lymphoma explode all trees
#13 MeSH descriptor Multiple Myeloma explode all trees
#14 MeSH descriptor Anemia, Aplastic explode all trees
#15 MeSH descriptor Bone Marrow Diseases explode all trees
#16 MeSH descriptor Thrombocytopenia explode all trees
#17 (thrombocytopeni* or thrombocytopenia* or leukemia or leukaemia or lymphoma* or aplastic anemia or aplastic anaemia or myelodysplas* or myeloproliferat* or multiple myeloma or plasma cell myeloma or thrombocythemi* or thrombocythaemi* or polycythemi* or polycythema* or polycythaemia* or polycythaemias* or AML or CLL or CML or Hodgkin*)
#18 ((haematolog* or hematolog* or blood or red cell* or white cell* or lymph* or marrow or platelet*) NEAR/3 (malignan* or oncolog* or cancer* or neoplasm*))
#19 MeSH descriptor Antineoplastic Agents explode all trees
#20 MeSH descriptor Stem Cell Transplantation explode all trees
#21 MeSH descriptor Bone Marrow Transplantation, this term only
#22 MeSH descriptor Radiotherapy explode all trees
#23 (chemotherap* or radiotherap* or chemoradiotherap* or stem cell* or bone marrow transplant* or rituximab)
#24 ((haematolog* or hematolog*) NEAR/2 patients)
#25 (malignan* or oncolog* or cancer* or neoplasm*)
#26 (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25)
#27 (#9 AND #26)
Appendix 2. MEDLINE (Ovid) search strategy

1. Antifibrinolytic Agents/
2. Tranexamic Acid/
3. exp Aminocaproic Acids/
4. (antifibrinolytic* or anti fibrinolytic* or antiplasmin* or plasmin inhibitor*).tw.
5. (tranexamic or cyclohexanecarboxylic acid* or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or kabi 2161 or transamin or exacyl or antifit or spotof or cyklodron or ugurol or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amfacharin or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexylamine carboxylic acid or aminomethyl cyclohexylamino carboxylic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanocarboxylic acid or amstat or antitoff or cl65336 or cl6536 or cyclocapron or cyclokapron or exacyl or frenolyse or hexacapron or hexakapron or TXA).tw.
6. (Agretax or Bio-Stat or Capiloc or Capitrax or Clip Inj or Clot-XL or Clotawin-T or Cymin or Dubtran or Examic or Existat or Extam or Fibran or Hemstate or Menogia or Monitex or Nestran or Nexamic or Nesi-500 or Nexmeff or Nixa-500 or Rheonex or Sylstep TX or Synostat or T-nex or T Stat or T Stat or Tnamic or Temsyl-T or Texanid or Texapar or Texid or Thams or Tonopan or Traklot or Tramic or Trimex or Tranarest or Trance Inj or Tranecid or Trancell or Tranec or Tranemic or Tranex or Tranexa or Tranfip or Tranlok or Transtat or Transys or Tranxi or Traptic or Traxage or Traxamic or Trenaxa or Traxemic or Trim Inj or Tx-1000 or Tx 500 or Wistran or X-Tran or Xamic).tw.
7. ((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic or amino caproic or aminon-hexanoic) adj2 acid*).tw.
8. (epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or acikaprin or afibrin or capracid or caprolak or caprolak or caproest or caprolak or caprolak or caprolysin or caprolak or hemocaprol or caproamin or EACA or caprolest or caprolak or hexalense or hamostat or homocid).tw.
9. (cl 10304 or ecapron or ekaprol or epsimon or epsilakmon or epsilon amino caproate or epsilon aminocaproate or epsilonaminocaproic or ethaaminocaproic or ethamaminocaproic or ethaaminocaproic or epocaprol or epsilakmon or epsilon amino caproate or epsilon aminocaproate or epsilonaminocaproic or Etamaminocaproic or epocaprol or hepoin or epsilon or jid?177or neocaprol or nsc? 26154 or tachostypan).tw.
10. or/1-9
11. exp Hematologic Neoplasms/
12. exp leukemia/ or exp lymphoma/
13. exp Multiple Myeloma/
14. exp Anemia, Aplastic/
15. exp Bone Marrow Diseases/
16. exp Thrombocytopenia/
17. (thrombocytopen* or thrombocytopena* or leukemia or leukaemia or lymphoma* or aplastic anemia or aplastic anaemia or myelodysplas* or myeloproliferat* or multiple myeloma or plasma cell myeloma or thrombocythemi* or thrombocythaemi* or polycythemi* or polycythemia* or myelofibros* or AML or CLL or CML or Hodgkin*).tw.
18. ((haematolog* or hematolog* or blood or red cell* or white cell* or lymph* or marrow or platelet*) adj3 (malignan* or oncolog* or cancer* or neoplasm*)).tw.
19. exp Antineoplastic Agents/
20. exp Stem Cell Transplantation/ or Bone Marrow Transplantation/ or exp Radiotherapy/
21. (chemotherap* or radiotherap* or chemoradiotherap* or stem cell* or bone marrow transplant* or rituximab).tw.
22. ((haematolog* or hematolog*) adj2 patients).tw.
23. (malignan* or oncolog* or cancer*).ti.
24. or/11-23
25. 10 and 24
Appendix 3. EMBASE (Ovid) search strategy

1. Antifibrinolytic Agent/
2. Tranexamic Acid/
3. Aminocaproic Acid/
4. (antifibrinolytic* or anti fibrinolytic* or antiplasmin* or plasmin inhibitor*).tw.
5. (tranexamic or cyclohexanecarboxylic acid* or tran-4-aminomethyl-cyclohexanecarboxylic acid* or r-amcha or kabi 2161 or transamin or exacly or anvisoff or spotof or cyklokapron or ugurol or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexancarboxylic acid or AMCHA or amfachibrin or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexancarboxylic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexancarboxylic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvisoff or cl65336 or cl6536 or cyclocapron or cyclokapron or exacly or frenolyse or hexacapron or hexakapron or TXA).tw.
6. (Agretax or Bio-Stat or Capiloc or Capitrax or Clip Inj or Clot-XL or Clotawin-T or Cymia or Dubatran or Examic or Existat or Extam or Fibran or Hemstate or Menogia or Monitex or Nestran or Nexmic or Nexi-500 or Nexmef or Nixa-500 or Rheonex or Sylstep TX or Synostat or T-nex or T Stat or T Stat or Tannic or Temsyl-T or Texakind or Texanis or Texapar or Texid or Thams or Tonopan or Traktol or Tramic or Tranix or Tranrest or Trance Inj or Tranecid or Tranee or Tranemic or Tranexor Tranexa or Tranfib or Tranlok or Transtat or Transys or Trapi or Tragic or Traxage or Traxamic or Trenaxa or Trenax or Trim Inj or Tx-1000 or Tx 500 or Wistran or X-Tran or Xamic).tw.
7. ((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic or amino caproic or amino-n-hexanoic) adj2 acid*).tw.
8. (epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or acikaprin or afibrin or capracid or capramol or caprogel or caproest or caprolisine or caprolysin or capromol or hemocaprol or caproamin or EACA or caprolest or capralense or hexalense or hamostar or hemocid).tw.
9. (cl 10304 or ecapron or ekaprol or epsimon or epsilamen or epsilon amino caproate or epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocap roich or emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc? 26154 or tachoportant).tw.
10. of/1-9
11. Hematologic Malignancy/
12. Lymphoma/
13. NonHodgkin Lymphoma/
14. Hodgkin Disease/
15. exp Myeloproliferative Disorder/
16. exp Aplastic Anemia/
17. exp Thrombocytopenia/
18. (thrombocytopeni* or thrombocytopaeni* or leukemia or leukaemia or lymphoma* or aplastic anemia or aplastic anaemia or myelodysplas* or myeloproliferat* or multiple myeloma or plasma cell myeloma or thrombocythemi* or thrombocythaemi* or polycytemia* or polycythaemia* or myelofibros* or AML or CLL or CML or Hodgkin*).tw.
19. ((haematolog* or hematolog* or blood or red cell* or white cell* or lymph* or marrow or platelet*) adj3 (malignan* or oncolog* or cancer* or neoplasm*)).tw.
20. exp Chemotherapy/
21. exp Stem Cell Transplantation/
22. exp Bone Marrow Transplantation/
23. exp Radiotherapy/
24. (chemotherap* or radiotherap* or chemoradiotherap* or stem cell* or bone marrow transplant* or rituximab).tw.
25. ((haematolog* or hematolog*) adj2 patients).tw.
26. (malignan* or oncolog* or cancer*).ti.
27. or/11-26
28. 10 and 27

Antifibrinolics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review) 44
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 4. CINAHL (EBSCOhost) search strategy

1. (MH Antifibrinolytic Agent)
2. (MH Aminocaproic Acids+)
3. (antifibrinolytic* or "anti fibrinolytic* or antiplasmin* or "plasmin inhibitor*)
4. TI (tranexamic or "cyclohexanecarboxylic acid" or "trans-4-aminomethyl-cyclohexanecarboxylic acid" or "t-amcha" or "kabi 2161" or transamin or exacly or anitoff or spotof or cyclokapron or ugurol or aminomethylcyclohexanecarboxylic acid or "aminomethylcyclohexanecarboxylic acid" or AMCHA or amchafibrin or amikapron or "aminomethyl cyclohexanecarboxylic acid" or "aminomethylcyclohexane carbolic acid" or "aminomethylcyclohexane carboxylic acid" or "aminomethylcyclohexanecarboxylic acid" or "aminomethylcyclohexanocarboxylic acid" or "aminomethylcyclohexanoic acid" or "aminomethylcy clohexanecarbonic acid" or "aminomethylcyclohexanecarboxylic acid" or "aminomethylcyclohexanocarbonic acid" or "aminomethylcyclohexanocarboxylic acid" or "aminomethylcy clohexanecarbonic acid" or AMCHA or amchafibrin or amikapron or "aminomethyl cyclohexane carboxylic acid" or "aminomethylcyclohexane carbolic acid" or "aminomethylcyclohexane carboxylic acid" or "aminomethylcyclohexanecarboxylic acid" or "aminomethylcyclohexanocarboxylic acid" or "aminomethylcyclohexanoic acid" or "aminomethylcy clohexanecarbonic acid" or "aminomethylcyclohexanocarbonic acid" or "aminomethylcyclohexanocarboxylic acid" or "aminomethylcy clohexanocarbonic acid" or "aminomethylcyclohexanoic acid" or "aminomethylcy clohexanecarbonic acid" or "aminomethylcyclohexanocarbonic acid" or "aminomethylcyclohexanoic acid"

5. TI (Agretax or "Bio-Stat" or Capiloc or Capitrax or "Clip Inj" or "Clot-XL" or "Clotawin-T" or Cymin or Dubatran or Examic or Exacly or Examin or Exami or Fibran or Fibrast or Menogia or Monitex or Nestran or Nexamic or "Nexi-500" or Nexmeff or Nixa-500 or Rheonex or "Sylstep TX" or Synostat or "T-nex" or "T Stat" or "T-xamis" or "T-xamis"

6. TI (epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or acikaprin or a fibrin or caprocid or caprolam or caprogel or caprolest or caprolisine or caprolysins or capromol or hemcaprol or caproamin or EACA or caprolest or Capralene or hexalense or hamostat or hemocid) OR AB (epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or acikaprin or a fibrin or caprocid or caprolam or caprogel or caprolest or caprolisine or caprolysins or capromol or hemcaprol or caproamin or EACA or caprolest or Capralene or hexalense or hamostat or hemocid)

7. TI (cl 10304 or ecaptor or ekaprol or epsamon or epsicaprion or epilcapramin or epislon aminocaprate or epislonaminocaproic or ethaaminocaproic or ethaaminocaproic or emocaprol or hepino or ipsilon or jd-177or neocaprolor nsc? 26154 or tachostyptan) OR AB (cl 10304 or ecaptor or ekaprol or epsamon or epsicaprion or epilcapramin or epislon aminocaprate or epislonaminocaproic or ethaaminocaproic or ethaaminocaproic or emocaprol or hepino or ipsilon or jd-177or neocaprolor nsc-26154 or tachostyptan)

8. S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8

9. S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8

10. (MH Hematologic Neoplasms+)

11. (MH Leukemia+)

12. (MH Lymphoma+)

13. (MH Bone Marrow Diseases+)

14. (MH Thrombocytopenia+)

15. TI (thrombocytopeni* or thrombocytopaeni* or leukaemia or leukaemia or lymphoma* or aplastic anemia or aplastic anemia or myelodysplas* or myeloproliferat* or multiple myeloma or plasma cell myeloma or thrombocythemi* or thrombocythaemi* or polyctyhem* or polyctyhaem* or myelofibros* or AML or CML or Hodgkin*)

16. TI ((haematolog* or hematolog* or blood or red cell* or white cell* or lymph* or marrow or platelet*) and (malignan* or oncolog* or cancer* or neoplasm*)

Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Review) 45
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
17. (MH Antineoplastic Agents)
18. (MH Chemotherapy, Cancer+)
19. (MH Hematopoietic Stem Cell Transplantation)
20. (MH Bone Marrow Transplantation+)
21. (MH Radiotherapy+)
22. TI (chemotherap* or radiotherap* or chemoradiotherap* or stem cell* or bone marrow transplant* or rituximab)
23. TI ((haematolog* N2 patients) or (hematolog* N2 patients))
24. TI (malignan* or oncolog* or cancer*)
25. S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24
26. S9 AND S25

Appendix 5. PubMed (epublications only)

#4 chemotherap*[tiab] OR radiotherap*[tiab] OR chemoradiotherap*[tiab] OR stem cell*[tiab] OR bone marrow transplant*[tiab] OR rituximab*[tiab]
#7 #2 OR #4 OR #5 OR #6
#8 #1 AND #7
#9 publisher*[sb] NOT pubstatusnihms
#10 #8 AND #9
Appendix 6. LILACS, KoreaMed, IndMed, PakMediNet search strategy
antifibrinolytic OR antifibrinolytics OR “anti fibrinolytic” OR “anti fibrinolytics” OR antiplasmin OR “plasmin inhibitor” OR tranexamic OR cyclokapron OR aminocaproic OR EACA OR amcha

Appendix 7. UKBTS SRI Transfusion Evidence Library search strategy
#1 (antifibrinolytic OR antifibrinolytics OR anti-fibrinolytic OR anti fibrinolytics OR antiplasmin OR plasmin inhibitor OR tranexamic OR amcha OR transamin OR exacyl OR amchafibrin OR anvitoff OR spotof OR cyclokapron OR ugurol OR amikapron OR amstar OR anvitoff OR cyclokapron OR cyclokapron OR exacyl OR frenolyse OR hexacakron OR hexakapron OR agretax OR Capiloc OR Capitrax OR Cymin OR Dubatran OR Examic OR Existar OR Extam OR Fibran OR Hemstate OR Monitex OR Nestran OR Nexamic OR Nexmef OR Nixa-500 OR Rheonex OR Synostar OR aminocaproic OR aminohexanoic OR amino caproic OR EACA OR amino-n-hexanoic OR epsikapron OR epsamon OR amicar OR caprocid OR akiprin OR capracid OR capramol OR caprogel OR caprolet OR caproisine OR caprolisin OR capromol OR hemocaprol OR caproamin OR caprolest OR capralense OR hexalense OR hemostat OR hemocid OR exacron OR ekaprol OR epsamon OR epsicapramin OR epsilon amino caproate OR epsilon aminocaproic OR ethaaminocaproich OR emcaprol OR hepin OR epsilon OR neocaprol OR tachostyptan)
#2 ((haematolog* OR hematolog* OR marrow OR platelet*) AND (malignan* OR oncolog* OR cancer* OR neoplasm*))
#3 (leukemi* OR lymphoma* OR chemothep* OR radiotherap* OR chemoradiotherap* OR stem cell* OR bone marrow transplant* OR rituximab OR “haematology patients” OR “hematology patients” OR “haematological patients” OR “hematological patients”)
#4 (malignan* OR oncolog* OR cancer*)[In Title]
#5 #2 OR #3 OR #4
#6 #1 AND #5

Appendix 8. Web of Science, Conference Proceedings Citation Index search strategy
(malignan* OR oncolog* OR cancer* OR neoplasm* OR chemothep* OR radiotherap* OR chemoradiotherap* OR stem cell* OR bone marrow transplant* OR rituximab OR “haematology patients” OR “hematology patients” OR “haematological patients” OR “hematological patients”) AND (antifibrinolytic OR antifibrinolytics OR anti-fibrinolytic OR anti fibrinolytics OR tranexamic OR aminocaproic OR EACA)

Appendix 9. ClinicalTrials.gov and ICTRP search strategy
Condition: malignan* OR oncolog* OR cancer* OR neoplasm* OR chemothep* OR radiotherap* OR chemoradiotherap* OR stem cell* OR bone marrow transplant* OR rituximab OR “haematology patients” OR “hematology patients” OR “haematological patients” OR “hematological patients”
AND
Intervention: antifibrinolytic OR antifibrinolytics OR anti-fibrinolytic OR anti fibrinolytics OR tranexamic OR aminocaproic OR EACA
Appendix 10. ISRCTN, EUDRACT, UMIN and Hong Kong Registry search strategy
antifibrinolytic OR antifibrinolytics OR anti-fibrinolytic OR anti fibrinolytics OR tranexamic OR aminocaproic OR EACA

CONTRIBUTIONS OF AUTHORS
Douglas Wardrop: protocol development and content expert.
Lise Estcourt: protocol development and content expert.
Susan Brunskill: protocol development and methodological expert.
Marialena Trivella: methodological expert.
Carolyn Doree: protocol development and search strategy expert.
Simon Stanworth: protocol development and content expert.
Mike Murphy: protocol development and content expert.

DECLARATIONS OF INTEREST
None declared.

SOURCES OF SUPPORT

Internal sources
- NHS Blood and Transplant, UK.

External sources
- German Ministry of Education and Research (BMBF) towards support of the Cochrane Haematological Malignancies Group, Germany.
Editorial support